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Primary brain tumours are a critical cause of morbidity and mortality in both adults and 
children, representing around 1-2% of all newly diagnosed tumours and accounting for 
about 2% of all cancer-related deaths. Gliomas are the most prevalent primary malignant 
brain tumour representing 80% of these. Over the past years, distinctive genetic profiles 
have been identified in several glioma types which have led to the WHO 2016 new 
classification of CNS tumours that incorporates molecular parameters into the tumour 
classification criteria, breaking with the previous approach based entirely on histological 
features. This refines tumour diagnostics and can also provide important prognostic and 
therapeutic response information. The aim of this study was to apply and verify if Next-
Generation Sequencing (NGS) can effectively replace the classical methods – 
pyrosequencing and Sanger sequencing - in establishing the molecular diagnostics of 
gliomas. Thus, a glioma-tailored gene panel covering 518 amplicons of 19 genes 
frequently aberrant in gliomas was designed and applied to assess 30 glioma samples. 
This targeted NGS approach was carried out by Illumina® TruSeq® technology in 
Illumina® MiSeq System. DNA libraries preparation showed a success rate of 90%. Data 
analysis was performed using several bioinformatical software and filtering parameters 
of variants were optimized to reduce sequencing artefacts in the NGS run. Better DNA 
quality libraries presented more reliable results showing less DNA sequence changes. The 
sensitivity and specificity of the 19-gene panel for detection of DNA sequence variants 
were verified by single-gene analyses which showed to be substantial concerning hotspot 
mutations but not so trustworthy concerning new-mutations detected by NGS. The 
presented findings showed that, even though NGS application in routine glioma 
molecular diagnostics can’t be yet implemented, further investigation of this technology 
is promising since NGS showed to be a resourceful tool for glioma genetic profiling, 
displaying its potential as diagnostic method which would facilitate the integrated 
histological and molecular glioma classification. 
 









Os tumores cerebrais primários são uma causa crítica de morbilidade e mortalidade em 
adultos e crianças, representando cerca de 1-2% de todos os tumores recém-
diagnosticados e cerca de 2% de todas as mortes relacionadas com o cancro. Os gliomas 
são o tipo de tumor cerebral maligno primário mais prevalente representando 80% destes. 
Ao longo dos últimos anos, foram identificados perfis genéticos distintivos em vários 
tipos de glioma o que levou à nova classificação de tumores do SNC de 2016, pela OMS, 
que incorpora os parâmetros moleculares nos critérios de classificação do tumor, 
quebrando com a abordagem anterior inteiramente baseada nas características 
histológicas. Esta nova abordagem veio aperfeiçoar o diagnóstico dos tumores e a 
capacidade de fornecer, também, informações importantes quanto ao prognóstico e 
resposta à terapêutica. O objetivo deste estudo foi aplicar e verificar se a Sequenciação 
de Nova Geração (NGS) pode efetivamente substituir os métodos clássicos - 
pirosequenciação e sequenciação de Sanger - no estabelecimento do diagnóstico 
molecular dos gliomas. Assim, foi desenhado e aplicado um painel genético adaptado a 
gliomas que cobriu 518 amplicões de 19 genes frequentemente aberrantes nestes, para 
analisar 30 amostras de gliomas. Esta abordagem direcionada da NGS foi realizada pela 
tecnologia TruSeq da Illumina®, no seu sistema MiSeq. A preparação das bibliotecas de 
DNA mostrou uma taxa de sucesso de 90%. A análise dos dados foi realizada recorrendo 
a vários softwares bioinformáticos e os parâmetros de filtração das variantes obtidas 
foram otimizados para reduzir os artefactos da sequenciação resultantes da execução da 
NGS. As bibliotecas de DNA de melhor qualidade apresentaram resultados mais 
confiáveis exibindo menos alterações nas sequências de DNA. A sensibilidade e a 
especificidade do painel de 19 genes para a deteção de mutações foram verificadas por 
análise individual dos genes, indicando ser substanciais em relação às mutações hotspot, 
mas não tão confiáveis em relação às novas mutações detetadas pela NGS. Os resultados 
apresentados mostraram que, apesar de não ser possível implementar para já a NGS na 
rotina do diagnóstico molecular de gliomas, é promissora uma investigação adicional 
nesta tecnologia, uma vez que a NGS mostrou ser uma ferramenta rica em recursos para 
delinear o perfil genético dos gliomas, ilustrando o seu potencial como método de 
diagnóstico que facilitaria a classificação histológica e molecular integrada dos gliomas. 
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“Tumours of the central nervous system (CNS) represent a relatively rare but serious 
health burden.” (1) 
In Europe, the estimated age-adjusted annual incidence of tumours of the Central Nervous 
System in 2012 was 6,6 cases per 100.000 individuals and its mortality rounded the 4,9 
cases per 100.000 individuals (Figure 1), according to the International Agency for 
Research on Cancer (IARC) (2). In that year, 57.000 new diagnoses and 45.000 deaths 
regarding tumours of the brain and other parts of the CNS were estimated in Europe (3). 
 
 
Figure 1 - Estimated incidence (A) and mortality (B) of brain and CNS cancer in both sexes in Europe, 
2012 
Illustrative representation of the number of individuals who were diagnosed, A, and died, B, for brain or 
other CNS tumour in 2012, in European countries; Western and Eastern countries are less affected when 
compared to central Europe; despite having high incidence, Northern countries own the lowest number of 
mortality reports associated with brain and other CNS cancer. (figure adapted from (2)) 
 
Brain tumours are classified into primary and secondary. Primary brain tumours are 
originated in the brain itself and they can be either malignant or benign oppositely to 
secondary brain tumours, which are metastasis originating from a tumour located in 
another part of the body and they are always malignant. These intracranial neoplasms are 
also subdivided into extracerebral tumours - meningiomas -, and intracerebral tumours 
which can be intrinsic – gliomas -, if they arise from the parenchyma of the brain or 





Primary brain tumours are a critical cause of morbidity and mortality in both adults and 
children (5), representing around 1-2% of all newly diagnosed tumours and accounting 
for about 2% of all cancer-related deaths (4,6). These tumours regularly cause severe 
disabilities and generate great distress not just in the patients, but also in their families 
and in the health care systems (5).  
Gliomas represent approximately 30% of all CNS tumours (7) and they are the most 
prevalent primary malignant brain tumours being responsible for 80% of these last 
mentioned (8,9,10). Worldwide, the annual incidence of these primary intracerebral 
neoplasms is about 6 cases per 100,000 individuals (11) and it is known that the western 
world has higher incidence of gliomas comparing to the less developed countries which 
could be explained by the deficient reporting of gliomas cases, limited access to health 
care and discrepancies in diagnostic practices (10). Glioma is derived from the Greek 
word for “glue”, as they emerge from CNS cells which form the scaffolding and structural 
support for neurons – astrocytes or oligodendrocytes (12). So, as gliomas occur in the 
glial tissue of the CNS, they share characteristics of the normal glial cell type that they 
most closely resemble histologically (7). Traditionally, these tumours are divided into 
two major categories based on the degree of invasiveness of the brain parenchyma: (i) 
gliomas with “circumscribed” growth behaviour and (ii) diffuse gliomas with diffuse 
infiltration of the brain parenchyma (13). Thus, gliomas are classified in line with those 
histological similarities and graded from I to IV based on morphology and malignant 
behaviour, according to the standard for nomenclature and diagnostics of CNS tumours: 
the World Health Organization (WHO) classification and grading system (8,3,14,10).  
The most typical gliomas found in adults include glioblastoma (grade IV), astrocytomas 
(grade I–III), oligodendrogliomas (grade II–III) and ependymomas (grade I–III) (8,14).  
It is known that there is a strong correlation between grade and prognosis: the higher the 
grade, the poorest the prognosis (3). 
Despite having diverse patterns of genomic variations and clinical outcomes, glioma 
patients most frequently bear a fatal prognosis which entails a substantial impact on them 
and their families’ physical, psychological and social status (8,15,16,17).  
The recognition of important genetic, epigenetic and transcriptional abnormalities in the 
several types of gliomas revolutionized the understanding of its physiopathology, its 
pathological classification, the patient treatment and novel therapeutic approaches, 





accurate classification and others are associated with therapy response and prognosis 
(17,18). 
 
The aim of this study was to examine the success and the advantages of using a modern 
parallel DNA sequencing technology – the Next-Generation Sequencing (NGS) – over 
the conventional single-gene-approach technologies – pyrosequencing and Sanger 
sequencing - in performing the molecular diagnostics of gliomas, mainly of previously 
histologically classified WHO grade IV glioblastomas, the most aggressive, invasive and 






1.1 Glioblastoma multiforme (GBM)  
WHO grade IV glioblastoma multiforme (GBM) is the most aggressive, invasive, 
undifferentiated and frequently occurring malignant type of brain tumour, accounting for 
more than 60% of all brain tumours (6,7,10). This malignancy is distinguished by its high 
degree of cellularity, microvascular proliferation, tumour cell chemoresistance and 
necrosis (6). 
GBMs are subdivided according to their clinical history as either primary GBM or 
secondary GBM, evolving through distinct genetic pathways, affecting patients at 
different ages and having various outcomes. Primary GBMs (arising de novo, in the 
absence of any precursor lesion), frequently IDH-wildtype, account for approximately 
90% of GBMs and is seen in older patients (mean age 62 years) with a rapid and robust 
disease progression. On the other hand, secondary GBM (arising from malignant 
progression of lower-grade astrocytoma or oligodendroglioma), generally IDH-mutant, 
occur in younger patients (mean age 44 years) with a longer history of disease progression 
and a better prognosis than primary GBMs (19,9,20,7,14). 
Despite the diversity of modern therapies, GBM is still an incurable disease with 
terrifically poor prognosis and a median survival of 15 months (19,10).  
 
1.1.1 Epidemiology 
GBM is considered the most prevailing brain and CNS malignancy in adults, representing 
approximately 50% of all gliomas (85% of malignant gliomas), 60% of all brain tumours 
(80% of malignant brain tumours) and 17% of all primary brain and CNS neoplasms 
(45,2% of malignant primary brain and CNS neoplasms) (10,19). About 17.000 new cases 
of this grade IV glioma are diagnosed per year (21). 
GBM can occur at any age but it is mainly diagnosed at older ages, with the median age 
of diagnostics of 64 years, and its incidence increases with age, being rare in paediatric 
population, uncommon before 20 years of age and reaching the peak at the 7th-8th decade 
of life (8,9,19,10). 
Men have a higher incidence of GBM as compared to women (information ratio 





even higher frequency in women. It is also known that white individuals have the highest 
rates for GBM when compared to the other ethnic groups. (19,10,21) 
 
1.1.2 Etiology and risk factors 
There is limited knowledge about the etiology of these highly incurable brain tumours 
(10).  Exposure to therapeutic or high-dose ionizing radiation is the only strongly 
established direct cause of GBM even after studying many genetic and environmental 
factors (9,22,10,19). Thus, GBM is considered mostly sporadic just like many other 
cancers (9,19).  
GBMs are reported to occur in families but there is no susceptibility gene identified yet. 
However, an association between some rare genetic disorders and an increased GBM 
incidence is established. So, screening is only performed in these individuals at genetic 
risk – e.g. neurofibromatosis type 1 and 2, tuberous sclerosis, Li-Fraumeni syndrome and 
Turcot syndrome (22,10,9,11). Also, several single-nucleotide polymorphisms (e.g. 
CDKN2B on chromosome 9p21) seem to be linked to an increased risk of GBM. These 
variants, found in at least 1% of a population, might disturb the physiological function of 
the gene product, accounting for individual differences in disease risk in sequence with 
other variants or exposures (19). 
Allergies or atopic diseases such as psoriasis, asthma and eczema, are associated with 
lower risk of GBM probably due to the activation of immune surveillance mechanism 
having a protective effect (23,24). Anti-inflammatory therapy use for short periods of 
time (<10 years) is also correlated with protective effect against GBM, particularly when 
there is no clinical history of allergies (25). 
GBM was linked to high-dose chemotherapy for cancer treatment at loci other than the 
brain, but the entity which determine the degree of risk from the exposure is individual 
genetics (22).  
To date no other significant evidence exists associating GBM with environmental factors 
or life-style aspects such as dietary exposure to N-nitroso compounds (e.g. cured or 
smoked meat or fish), smoking, alcohol consumption and drugs usage, pesticide 
exposure, severe head injury or even exposure to diagnostic radiation. Additionally, no 
conclusive association has been found between the use of mobile phones and the risk of 





1.1.3 Prognosis, treatment and survival  
In clinical oncology, GBM treatment remains one of the most challenging assignments, 
despite all international attempts. Over the past few years, diverse therapies have been 
investigated with very limited success (19). 
The location and the complex heterogeneous nature of these tumours is the great 
responsible for the difficulty in effectively treating GBM patients (28,19). 
Presently, standard management of GBM includes not only specific anti-tumour therapy 
but also implementing efficient supportive care to the patient in order to handle the 
various symptoms and signs of the disease (e.g. corticosteroids for neurological 
symptoms relief; Levetiracetam for patients with seizures). The current accepted 
antineoplastic treatment for GBM patients involves neurosurgical resection followed by 
radiation therapy and concurrent aggressive chemotherapy with oral temozolomide 
(TMZ) 75 mg/m² daily and then succeeded by six cycles of maintenance treatment with 
oral TMZ 150–200 mg/m² for 5 days every 4 weeks. However, in most cases recurrences 
emerge and they can be managed with additional surgery and adjuvant treatment with 
antiangiogenic (e.g. Bevacizumab) or chemotherapeutic (e.g. Carmustine and Lomustine) 
drugs. Marginal benefits are observed but patients most frequently die (7,28,19,11,29). 
Hence, with no effective treatment against GBM in the current time, this malignancy 
remains incurable carrying a deadly poor prognosis. GBM patients have a median life-
expectancy of only 15 months after diagnostics and the 5-year survival is 2-4% (21,6,30). 
 
1.1.4 Site and clinical presentation 
GBM is most frequently situated in cerebral hemispheres, occurring essentially in the 
supratentorial region (primary GBMs arise in any lobe with a widespread distribution, 
whereas secondary GBMs have a striking predilection for the frontal lobe) and only few 
percent of these neoplasms arise in cerebellum (0.4-3.4%) and even more rarely in the 
brainstem and spinal cord (31,19).  
GBM patients often present a short clinical history, ranging between 1 to 6 months. For 
patients with secondary GBM clinical history can extend to a few years (10,8,32). 
Different signs and symptoms may be present in GBM patients, some are results of the 





(10). Hereby, GBM clinical presentation features include essentially focal neural deficits 
- the most common symptom (40-60%) -, neurocognitive impairment, epileptic seizures, 
headache, vomiting and altered consciousness (11,10,8).  
 
1.1.5 Macroscopic and histological features 
Macroscopically, the tumour is typically represented by single, relatively large, irregular 
shaped lesion having a ring-shaped zone of contrast enhancement around a dark, central 
area of necrosis, which usually arises in the white matter (Figure 2). Regardless of their 
feature heterogeneity, GBM is known for significant and consistent multifocal 
haemorrhage, necrosis and exuberant vascular hyperplasia (30,33,34).  
In addition to imaging findings a tissue analysis is required for definitive 
histopathological confirmation and to discriminate from other primary and metastatic 
brain tumours (35). 
Histologically, GBM presents hypercellularity with a pleomorphic cell population 
varying from small poorly differentiated tumour cells to large multinucleated cells, 
nuclear atypia, prevalent mitotic activity and its major characteristic features of 
microvascular proliferation, frequently with glomeruloid structure and multifocal 
necrosis with pseudopalisading cells (Figure 3) (13,16,33,10,36).  
 
 
Figure 2 - Representative radiological findings of GBM in four different patients 
Contrast-enhanced axial images illustrate the heterogeneity of the tumour: (a) rim-enhancing mass with 
central necrosis and surrounding edema in the right parietal lobe; (b) irregularly enhancing mass crossing 
the corpus callosum; (c) well-circumscribed homogeneously enhancing mass with no combined edema in 
the left frontal lobe; (d) poorly-defined infiltrative mass in the left medial frontal lobe with no significant 






Figure 3 - Histopathologic feature of a medium-sized (200-400µm) pseudopalisade in GBM 
Pseudopalisades are the key-features to histologically distinguish GBM from other adult gliomas, 
presenting central necrosis, central vacuolization, individual dying cells and typical peripheral zone of 
fibrillarity right inside the feature. (figure adapted from (37)) 
 
1.1.6 Genetic and molecular pathology: the key to diagnostics 
There are six main intracellular events featuring glioma and the combination of multiple 
of those oncogenic occurrences are the cause and sustenance of GBM (38): (i) loss of cell 
cycle control, (ii) genetic instability (iii) overexpression of growth factors and their 
receptors, (iv) invasion and migration, (v) abnormality of apoptosis and (vi) angiogenesis 
(38). The genomic profiling which has been used to identify the genetic abnormalities 
underlying GBM tumorigenesis (39), brought a set of genes whose alterations serve as 
tumour classification/diagnostic, prognostic and therapy response biomarkers, 
demonstrating its significant genetic heterogeneity  (40,41).   
Primary GBMs are mostly characterized by EGFR gene-amplification and 
overexpression, PTEN mutations, TERT promotor mutations, loss of heterozygosity 
(LOH) of chromosome 10q and they typically lack IDH1/2 mutations, which carry the 
worst prognosis. In contrast, the hallmarks of secondary GBMs include mutations in 
IDH1/2, TP53 and ATRX genes and LOH of 19q, which are biomarkers associated with 
longer survival (42,41,10,34,19). Paediatric GBMs, a unique malignancy, most 
commonly feature alterations in H3F3A, ATRX and TP53 genes and rarely feature IDH 
mutations (43,41,42). 
Table 1 summarizes the most frequently mutated genes in gliomas and represents the list 


















Receptor Type 1 




Member of the bone morphogenic 
protein (BMP) signalling pathway: type 
I BPM receptor, which is activated in 
response to extracellular BMP, 
phosphorylating and activating 
downstream growth  
 
Gain of function: constitutive activation 
of the BMP signalling pathway, leading 













ATRX Chromosome X; 
nucleus 
DNA helicase crucial in chromatin 
remodelling and maintenance of 
telomeres 
 
Loss of function: alternative 
lengthening of telomeres (ALT) 






















e Kinase  




Strongly activates the extracellular 
signal-regulated/mitogen-activated 
protein kinase 1 and 
2 (MAPK/ERKs) signalling pathway, 
playing a key-role  
in cellular division, survival and 
metabolism 
Gain of function: constitutive activation 
of the MAPK/ERKs signalling 
pathway, leading to uncontrolled cell 
proliferation 
 
Most frequent BRAF mutations occur at amino 


















Rare in adult HGG (2–5%) 
but more frequent in 
paediatric GBMs with  






CIC Chromosome 19; 
nucleus 
Transcriptional repressor of receptor 
tyrosine kinase (RTK) signalling 
pathway 
Loss of function: activation of RTK 
signalling pathway leading to 
upregulation of genes involved in cell 
proliferation 
 
Associated with 1p/19q codeletion  
 
Oligodendrogliomas 
Grade II-III (52%) 
  
Rare 
















Transmembrane receptor which binds to 
epidermal growth factor (EGF) 
initiating the EGFR signalling pathway 
which leads to transcription and cell 
proliferation 
Gain of function: uncontrolled cell 
proliferation 
 
Primary GBM (40%) 
 












Member of EGFR pathway whose 
activation leads to transcription and cell 
proliferation   
Gain of function: constitutive activation 
of the EGFR signalling pathway, 












RTK whose extracellular portion 
interacts with fibroblast growth factors, 
regulating mitogenesis, proliferation, 
differentiation, cellular migration and 
angiogenesis 
















FUBP1 Chromosome 1; 
nucleus 
Regulates c-Myc proto-oncogene 
expression by binding to its far-
upstream element (FUSE) 
Gain of function: stimulation of c-Myc 




Grade II-III (30%) 
 
Rare  











Nuclear proteins responsible for the 
complex post-translational epigenetic 
expression by mediating changes in the 
DNA heterochromatin structure and 
conducting the interactions of 
transcriptional activators and repressors 
Loss of function: continued 
transcription leading to uncontrolled 
cell proliferation   
 
Most frequent mutations are SNVs leading to 
substitutions G34R/V or K27M  
Paediatric and young 
adult HGG 




Cluster 1 Family 
















IDH family catalyse the oxidative 
decarboxylation of isocitrate to α-
ketoglutarate (α-KG), vital to metabolic 
processes, while 
converting NADP+ to NADPH, which 
protects the cell from reactive oxygen 
species (ROS)  
 
Preferential affinity for α-KG than for 
isocitrate leading to a neomorphic 
activity that mediates the abnormal 
formation of the oncometabolite 
hydroxyglutarate (2-HG) as a result of 
NADPH-dependent reduction of α-KG:  
 - inhibition of multiple α-KG-
dependent enzymes leading to 
epigenetic changes: hypermethylation 
at large number of genes resulting in 
gene expression alterations and 
inactivation of tumour supressors; 
increased histone methylation at 
oncogenic sites (H3k27), resulting in a 
blockage to cell differentiation and 
uncontrolled cell proliferation 
- hypersensibility to ROS and oxidative 
damage 
 
Featured by single amino acid substitutions 
replacing arginine in codons 132 of IDH1 or 172 
of IDH2; IDH1 R132H is the most prevailing 













Primary GBM (3–7%)   





















suppressor which is a negative regulator 
of Ras and mechanistic target of 
rapamycin 
(mTOR) signalling pathways  
 
Loss of function: enhancement of 
Ras/MAPK/ERKs signalling pathway, 






PIK3CA Chromosome 3; 
cytosol, plasma 
membrane 
Member of the oncogenic receptor 
tyrosine kinase/phosphoinositide 3'-
kinase/a serine-threonine kinase 
(RTKs/PI3K/Akt) signalling pathway 
which regulates cell growth, survival, 
proliferation, motility and adhesion  
Gain of function: constitutive activation 
of the RTKs/PI3K/Akt signalling 
pathway, leading to uncontrolled cell 


















PPM1D Chromosome 17; 
nucleus 
Member of the PP2C family of 
serine/threonine protein phosphatases 
which negatively regulates cell stress 
response pathways as a negative 
regulator of TP53 tumour suppressor 
 











Tumour suppressor which negatively 
regulates the oncogenic 
RTKs/PI3K/Akt signalling pathway by 
antagonizing PI3K function  
 
Loss of function: activation of the 
RTKs/PI3K/Akt signalling pathway, 
leading to uncontrolled cell 
proliferation, cell invasion and blood 
vessel formation 
 
PTEN deletion associated with LOH of 
chromosome 10q 
 












TERT Chromosome 5; 
mitochondrion, 
nucleus 
Ribonucleoprotein polymerase that 
regulates the length of telomere ends of 
chromosomes 
 
Inactive or very low activity in most of adult cells 
Gain of function: cellular 
immortalization and proliferation 
 
Most frequent TERT mutations occur at positions 
228 and 250 in the TERT 
promotor 
























Tumour suppressor and transcription 
factor which coordinates cell responses 
to cellular stresses by regulating genes 
involved in cell division 
(downregulation) or apoptosis 
(upregulation) 
Loss of function: apoptosis inhibition 












*Not yet specified                                                                                      (genomic locations and main subcellular locations were collected resorting http://www.genecards.org/) 
DIPG – diffuse intrinsic pontine glioma 
HGG – High-grade glioma 






1.2 Prioritizing molecular markers in the diagnostics of brain 
tumours 
For the past century and until recently, the standard principles used by neuropathologists 
towards the diagnostics and classification of brain tumours have been based 
predominantly on histological concepts which categorized tumours according to their 
microscopic similarities with the origin cells and supposed differentiation levels, defined 
in the 2007 version of the WHO classification (16,14). Despite this histologic-based 
classification system resulted of constant updates and evolved over the years, it carries 
several limitations, such as inconclusive histological features due to microscopic 
similarities between different entities, inter-observer variability and insufficient or non-
representative tissue sampling. Hence, it is known that patients with morphologically 
identical neoplasms may experience different clinical outcomes and treatment responses 
due to distinct underlying genetic features of the tumours. As such, there is increased 
evidence that histologically ambiguous gliomas may be more precisely classified 
resorting genetic markers (16,18,63). A notorious example is the controversial group of 
oligoastrocytomas which can turn out to fit into either diffuse astrocytomas or 
oligodendrogliomas, depending on three genetic markers: IDH1/2, 1p/19q codeletion and 
loss of ATRX (18), as displayed in Figure 5. 
Emphasizing the increasing impact of molecular information, the WHO 2016 new 
classification of the CNS tumours incorporated molecular parameters into the tumour 
classification criteria, breaking with the previous approach based entirely on microscopy 
(8,14). Presently, a CNS tumour classification consists of a histopathological name 
followed by the genetic features (e.g. Glioblastoma, IDH-mutant), as seen in Figure 4. 
When tumours have not been fully tested for the relevant genetic parameters, a diagnostic 
designation of NOS (not otherwise specified) may be acceptable (14). 
Hence, GBMs are subdivided in the 2016 WHO classification of CNS tumours into (a) 
glioblastoma, IDH-wildtype which corresponds to the clinically defined primary GBM 
(90% of cases); (b) glioblastoma, IDH-mutant, which corresponds to the secondary GBM; 
(c) glioblastoma, NOS, when full IDH assessment cannot be performed (Figures 4, 5 and 





Each glioma subtype has its feature molecular profile, differing from each other and 















Figure 5 - Simplified algorithm for the diffuse gliomas integrated classification 





“The use of “integrated” phenotypic and genotypic parameters for CNS tumour 
classification adds a level of objectivity that has been missing from some aspects of the 
diagnostic process in the past.” (14) 
 
 
Figure 6 - Key features of IDH-wildtype and IDH-mutant GBMs 
(figure adapted from (14)) 
 
Thus, this new integrated brain tumour classification is expected to lead to greater 
diagnostic certainty, enhanced patient management and more accurate determinations of 
prognosis and treatment response, highlighting the importance of the molecular 
parameters in these matters. 
Additionally, despite several genetic alterations can be already detected resorting to 
immunohistochemistry or FISH, including IDH1 R132H, ATRX loss, H3 K27M and 
1p19q codeletion (11), DNA sequencing is imperative to allow a richer analysis capable 
of fully respond to the increasing requirements for better molecular and clinical 





1.3 Next-Generation Sequencing (NGS) pathway towards molecular 
diagnostics  
Succeeding the increased importance of molecular parameters in the clinical outcomes, 
an extensive molecular profiling is crucial for tumours of the CNS in order to improve 
their management. Next-Generation Sequencing (NGS) technology answers to this 
require, providing the opportunity to analyse a large set of molecular targets in a 
massively paralleled approach, still granting high accuracy and sensitivity because of its 
high sequencing coverage (64,63). 
 
1.3.1 The evolution of genomic technologies: DNA sequencing timeline  
In 1944, Avery McLeod and McCarthy showed that the DNA was the material from 
which genes were composed and since that legendary experiment the knowledge 
regarding DNA is constantly growing (65). In 1953, Watson and Crick made the next 
significant discovery in the genetics field proposing a double helix as the structure model 
of DNA, which is still the central principle of molecular biology (65,66). Sequencing 
technology emerged as the set of methods to determine the primary structure of DNA, 
allowing to learn about the order of the four nucleotides (A, C, G, T) in the DNA, which 
remains the growing interest in genetics (65). Bacteriophage Phi-X174 was the first 
organism whose genome was completely sequenced, in 1977, resulting from the 
development of the first-generation DNA sequencing technique: Sanger’s ‘chain-
terminator’ or di-deoxy method. This was the sequencing gold standard until the late 
2000’s and it is still one of the most reliable methods to establish molecular diagnostics, 
along with pyrosequencing technology, later developed in 1996 (66,65,67).  
As a result of enthusiastic massive sequencing projects (e.g. human genome), it was 
fundamental to develop a new technology which carried less costs and required less time 
to collect the sequences and hereby emerged the Next-Generation Sequencing (NGS) 
(65,67): “a high-performance technology based on the parallelization of the sequencing 
process, resulting in the reading of thousands or millions of sequences simultaneously” 
(65). It was in 2004 when the first NGS sequencer, 454 Roche (based on pyrosequencing 
technology), was commercialized and ever since the increased research in NGS has 
launched eight large massive sequencing platforms to the market and the NGS associated 





1.3.2 NGS: a technology with unique features  
Next-Generation Sequencing (NGS), including second- and third-generation sequencing 
technologies, universally refers to those technologies which are able to massively parallel 
sequence millions of DNA templates, allowing to analyse a large number of samples 
simultaneously. This demonstrates the evolution of the conventional sequencing 
techniques in which only one or a few short fragments of DNA previously amplified by 
Polymerase Chain Reaction (PCR) could be sequenced per tube. This great progress was 
allowed not only by innovation in sequencing chemistries but also by better imaging, 
microfabrication and information technology (68,67,69).  
 
1.3.2.1 NGS landscape  
Currently, this advanced sequencing technology is subdivided in two major categories: 
short- and long-read sequencing (68). According to the DNA sequencing method, there 
are several NGS sequencers available (Table 2). The eight distinct platforms presently 
available diverge from each other concerning not only the general parameters such as 
preparation of the templates for sequencing, the sequencing chemistry itself and the 
detection system utilized (70) but also specific intrinsic parameters (equipment, accuracy, 
numbers of readings and, consequently, cost for each sequencing reaction) (71).  
 
Table 2 - NGS sequencers presently available in the market 
Short-read sequencing technology can be performed through either sequencing by ligation or sequencing 
by synthesis. Sequencing by synthesis sequencers are those with generally better relationship between cost 
($10-100/Gb, excepting for 454 Roche which is the most expensive of the sequencers with a cost of 
$10.000/Gb), accuracy (99-99.9%) and time of run (2h-3days). Illumina is currently the most frequently 
used platform because of its lowest cost associated with highest number of bases read per run. Sequencing 
by ligation sequencers, despite being as cheap and as accurate as Illumina’s ($10/Gb; 99.9%), have the 
longer run time (7 days) and the lowest read length (75 bp) comparing to all other sequencers. Long-read 
sequencing sequencers are associated with higher costs ($600-1000/Gb) and lower accuracy (90%) due to 
their highest read lengths in line of the thousands (65,67,70,69).  (adapted from: (65)) 
Methods of DNA Sequencing Platforms 
Short-read 
sequencing 
Sequencing by ligation 
AB SOLiD (Thermo Fisher) 
Complete Genomics (BGI) 
Sequencing by 
synthesis 
















1.3.2.2 Illumina’s platform 
The short-read sequencing method is currently the most frequently used approach due to 
its low costs per Gb and high accuracy (67). As such, the sequencers most extensively 
used in the development of massive sequencing projects, including diagnostic purposes, 
are Illumina’s (MiSeq/HiSeq/NextSeq), not only due to the previously referred features 
associated with short-reading sequencing method but also because of the great diversity 
of equipment present in the market adapted to the needs of each project (65,41). As 
general features, Illumina’s platform have a mean read length of 300 bp, an accuracy of 
99,9%, a run time of 3 days and it processes 1800 Gb per run with a symbolic cost of 
$10/Gb (65). Basically, Illumina’s platform performs DNA sequencing resorting to 
fluorescence-labelled nucleotide analogues which act as reversible terminators of the 
amplification reaction, differing from the Sanger sequencing whose DNA polymerization 
stoppage is irreversible. This NGS technology has a unique feature: it carries out the 
clonal amplification in situ by bridge PCR, joining the DNA templates to immobilized 
primers present on a solid surface (flow cell) then generating clusters of DNA composed 
of equal molecules and the fluorescence emission wavelength and intensity directly 
recorded during sequencing process are used to identify the base incorporated (65,72).  
 
1.3.2.2 Targeted-sequencing 
Different approaches can be pursued according to the goal of the project in mind – whole 
genome, whole exome or targeted sequencing. As the first both are expensive, time-
consuming and difficult to perform with the small amounts of DNA (e.g. brain biopsy), 
targeted sequencing (or re-targeted, when the genes designed to assess were previously 
studied by the conventional methods) is the method of choice for most clinical 
applications (e.g. diagnostics, prognostics and predict treatment response), allowing to 
study the genetic alterations of a neoplastic tissue (63,67). Targeted sequencing is 
performed resorting to gene panels which can be purchased with preselected content or 
custom designed including the genomic regions of interest (ROIs). As such, they have the 
ability of detecting genetic variations such as single-nucleotide variations (SNVs), 
insertions and deletions, copy number changes and gene fusions, in a cost-efficient and a 
high-coverage of ROIs manner (63,67). There are various targeted NGS panels available 
in the market, but not even one is designed to specifically target the critical genetic 





1.3.3 Prevailing pros and cons of NGS technology for glioma diagnostic routine 
NGS technology brought three significant enhancements from the standard traditional 
Sanger sequencing and pyrosequencing methods: (i) NGS do not require previous 
amplification of DNA fragments by PCR or bacterial cloning; (ii) NGS can in one 
sequencing reaction analyse multiple genes/ROIs of multiple samples, handing out the 
need of hundreds of sequencing reactions which would be needed if one would use 
conventional technologies (analyse one gene from one sample per sequencing reaction); 
(iii) NGS outputs are directly detected oppositely to Sanger sequencing which requires 
further electrophoresis (69). As such, short-read sequencing platforms, e.g. Illumina’s, 
provide a cost- and time efficient alternative to currently used conventional sequencing 
techniques, which follow the single-gene-approach, and, resorting to the gene panels 
approach, it could theoretically be implemented for routine cancer diagnostics (67,41).  
However, NGS has not yet been installed in routine brain tumour diagnostics and so 
neither has replaced the established traditional methods due to the lack of sufficiently 
powered studies providing evidence that NGS is reliable enough for this purpose (64,41). 
The paucity of evidence is the consequence of the remaining great challenges of this new 
technology: (a) how to most efficiently filter all data outputs in order to select the 
important mutations and distinguish them from potentially false-positives, e.g. result of 
poor-quality DNA artefacts and (b) how to manage all information and non-traditional 
sorts of findings, such as novel mutations which can or cannot be clinically significant 
(64,67,73).  
 
Hence, and being the major guide of the present study, it is imperative to deeply study all 
NGS method-related features in order to determine its leverage when performing the 
molecular diagnostics of brain tumours comparing to the gold-standard classical 





2  SCOPE OF THE STUDY 
This study is focused on the molecular diagnostics of brain tumours and it was developed 
at the Brain Tumour Reference Centre of Germany. 
For the first time, WHO 2016 Classification of Brain Tumours includes molecular 
parameters in addition to histology to establish the diagnostics of many tumour entities 
(14). The more important molecular diagnostics of brain tumours get, the more crucial is 
to improve the pathways to achieve it. Single-gene approach, such as pyrosequencing or 
Sanger sequencing technologies, is the most used classical way to determine the 
molecular diagnostics of brain tumours.  
In this study, the main goal is to apply and verify if NGS technology could effectively 
replace the classical methods to establish glioma’s molecular diagnostics. In this purpose, 
two approaches were scrutinized: 
1) Detection of “old mutations” –  assessment of NGS ability to correctly detect 
well-known and described mutations, such as hotspot mutations in codon 132 of 
IDH1, in codon 600 of BRAF and in codons 27 and 34 of H3F3A, through further 
validation with pyrosequencing single-gene analysis. Also, six glioma DNA 
samples with several different molecular diagnostics already performed by 
pyrosequencing analysis were added in the study to evaluate the accuracy of NGS 
technology concerning the detection of the mutations already identified with the 
classical method.  
2) Analysis of “new mutations” – NGS mutation results are endless. Many “new” 
(not known or described) mutations are displayed in NGS outputs, but are they 
real or just artefacts? In this concern, an extensive data analysis of NGS outputs 
through a good filtering process considering all technical and biological factors 
shall be done to allow a selection of the most promising novel mutations to further 
evaluate and possibly validate with the gold-standard Sanger sequencing 
technology. 
Thus, an overall analysis of NGS technology characteristics was performed to appraise if 
NGS pros mute NGS cons regarding those of the classical technologies currently 





3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 FFPE DNA Samples 
Twenty-four DNA samples from GcGBM were selected to analyse: twelve from adult 
patients and the other twelve from children patients; in addition, six samples from other 
gliomas with molecular diagnostics already performed and known were used as controls 
(n = 30) (Table 3). 
All of the DNA samples were formalin-fixed paraffin-embedded (FFPE) preserved from 
surgically removed CNS tumours and the DNA was extracted using the QIAamp DNA 
FFPE Tissue Kit. 
 
Table 3 - Samples’ ID correspondences 
In this table it is represented each DNA sample ID (bold) and the correspondent number for each (sample 
X) further used in this study to simplify the terminology and the graphing. The first 24 samples (1-24) are 
from GcGBM and the last six (25-30) are from other glioma samples which were used as controls. 
Sample ID 
585 Sample 1 4121 Sample 16 
588 Sample 2 4122 Sample 17 
748 Sample 3 4125 Sample 18 
2489 Sample 4 4129 Sample 19 
4099 Sample 5 4142 Sample 20 
4100 Sample 6 4153 Sample 21 
4101 Sample 7 4155 Sample 22 
4102 Sample 8 4158 Sample 23 
4107 Sample 9 4160 Sample 24 
4109 Sample 10 R-78610 Sample 25 
4110 Sample 11 P-3879 Sample 26 
4111 Sample 12 R-78222 Sample 27 
4118 Sample 13 R-78653 Sample 28 
4119 Sample 14 R-77342 Sample 29 







Table 4 - Primers for amplification of glioma gDNA for hot spot mutations analysis 
Gene (locus) Primer sequence 
BRAF (codon 600) fw: 2708 5’ GAAGACCTCACAGTAAAAATAG 3’ 
rev: 2709 5’ Biotin-ATAGCCTCAATTCTTACCATCC3’ 
IDH1 (codon 132) fw: 2134 5’ CACCATACGAAATATTCTGG 3’ 
rev: 2137 5’ Biotin-CAACATGACTTACTTGATCC 3' 
H3F3A (codon 27 and 34) fw: 2711 5’ TGTTTGGTAGTTGCATATGG 3’ 
rev: 2712 5’ Biotin-TACAAGAGAGACTTTGTCC 3’  
 
Table 5 - Primers for pyrosequencing of amplified glioma gDNA for hot spot mutations analysis 
Gene (locus) Primer sequence 
BRAF (codon 600) ps: 2710 5’ AGGTGATTTTGGTCTAGCTACAG 3’ 
IDH1 (condon 132) ps: 2136 5’ GTGAGTGGATGGGTAAAACC 3’ 
H3F3A (codon 27 and 34) ps: 2705 5’ CAAAAGCCGCTCGCA 3’ 
 
3.1.3 Molecular biological kits 
3.1.3.1 Next-Generation Sequencing (NGS)  
a) Input DNA quantification: QUBIT 
Qubit® dsDNA BR Assay Kit 
Qubit® dsDNA BR Reagent 
Qubit® dsDNA BR Buffer  
Qubit® dsDNA BR Standard #1 
Qubit® dsDNA BR Standard #2 






b) Libraries preparation 
Table 6 - Low Input Library Prep Kit contents 
 
Illumina® TruSeq® Custom Amplicon                                        
Index Kit (384 samples) 
Illumina Inc (Ense-Höingen,  
Germany) 
Table 7 - Index Kit contents 
i5 Index Adapter Sequence Index replacement caps 
A501 TGAACCTT 









i7 Index adapter Sequence Index replacement caps 
A701 ATCACGAC 














Illumina® TruSeq® Custom Amplicon 
Low Input Library Prep Kit (96 samples) 
Illumina Inc (Ense-Höingen, 
Germany) 
























c) Assessing libraries’ preparation success 





DNA Dye Concentrate  
DNA Gel Matrix  
DNA Ladder 
 DNA Markers 
 
Agilent Technologies (Waldbronn, 
Germany) 




PyroMark PCR Kit 
Mater mix 2x 
CoralLoad concentrate 10x 
H2O 
    Qiagen (Hilden, Germany) 
PyroMark GoldReagents Kit 
PyroMark Annealing Buffer 
PyroMark Binding Buffer, pH 7,6 
PyroMark Denaturation Solution 
PyroMark Enzyme Mixture 
PyroMark Nucleotides (dATP, dCTP, 
dGTP, dTTP) 
PyroMark Substract Mixture 
PyroMark Wash Buffer, pH 7,6  





3.1.3.4 Sanger Sequencing   
Crude PCR products prepaid Kit 
96 Clean-ups of crude PCR products 
96 sequencing reactions 
Barcode labelled green 96-well plate 
Twelve 8-cap strips for sealing 
Shipping box 
Pre-paid, pre-addressed, shipping          
envelope 
 
Eurofins Genomics (Ebersberg, 
Germany) 
3.1.4 Other chemical substances and solutions  
Table 8 - Other chemical substances and solutions used in this project 
Boric acid  Roth Chemie GmbH (Karlsruhe, 
Germany) 
EDTA (0,5M; pH8,0) Roth Chemie GmbH (Karlsruhe, 
Germany) 
Ethanol absolute  PanReac AppliChem (Darmstadt, 
Germany) 
HPLC Water Avantor Performance Materials 
B.V. (Deventer, Netherlands) 




Merck KGaA (Darmstadt, Germany)  
peqGOLD Universal Agarose  PEQLAB Biotechnologie GmbH 
(Erlangen, Germany)  
pUC19 DNA ladder Thermo Fisher Scientific (Schwerte, 
Germany) 
Streptavidin-Sepharose High Performance 
Beads 
GE-Healthcare (Solingen, Germany) 







3.1.5 Technical equipment and other materials  
Table 9 - Technical equipment and other materials used in this project 
Technical equipment 
Agilent 2100 bioanalyzer  Agilent Technologies (Waldbronn, 
Germany) 
Centrifuge HERAEUS RS 3.0 Thermo Fisher Scientific (Schwerte, 
Germany) 
CarlRothTM Mini-centrifuges Thermo Fisher Scientific (Schwerte, 
Germany) 
Gel electrophoresis chamber (Sub-
Cell® GT Cell) 




INFINITYT 3000 Imaging Systems PeqLab Biotechnologie GmbH 
(Erlangen, Germany) 
Monoshake Microplate Shaker  Variomag®-USA (Daytona Beach, 
Florida, USA) 
Quantum ST4 3000 
 
Montreal Biotech (Montreal, 
Canada) 
NGS Sequencer (Illumina® MiSeq System)  Illumina Inc (Ense-Höingen, 
Germany) 
PCR machine (thermal cycler Biometra 
TRIO) 
Biometra (Göttingen, Germany) 
pH meter  
 
Mettler Toledo (Giessen, Germany) 
PowerPac™ Basic Power Supply 
 
Biorad (Munich, Germany) 
PyroMark Q24 Instrument, Biotage 
 
Qiagen (Hilden, Germany) 
PyroMark Q24 Vacuum Workstation 
 
Qiagen (Hilden, Germany) 
PyroMark Q24 Plate  
 





PyroMark Q24 Cartridge 
 
Qiagen (Hilden, Germany) 




Biometra (Göttingen, Germany) 




Kern (Balingen, Germany) 
Other materials 
Eppendorf® tubes 0.5, 1.5, 2 mL  
 
Eppendorf (Hamburg, Germany) 
FalconTM Conical Centrifuge Tubes 15,50 
mL  
Thermo Fisher Scientific (Schwerte, 
Germany) 
Magnetic stand-96 Thermo Fisher Scientific (Schwerte, 
Germany) 
Microseal® ‘A’ PCR Plate Sealing Film Bio-Rad Laboratories GmbH 
(Munich, Germany) 
Microseal® ‘B’ PCR Plate Sealing Film  Bio-Rad Laboratories GmbH 
(Munich, Germany) 
MiSeq Flow Cell 
 
Illumina Inc (Ense-Höingen, 
Germany) 
MiSeq Reagent Cartridge 
 
Illumina Inc (Ense-Höingen, 
Germany) 
PCR 8-tube strips Thermo Fisher Scientific (Schwerte, 
Germany) 
96-well midi plates Thermo Fisher Scientific (Schwerte, 
Germany) 







3.1.6 Software and Databases  
Table 10 - Software and databases used in this project 
Catalogue of Somatic Mutations in 
Cancer (COSMIC) 
Wellcome Trust Sanger Institute 
(Hinxston, UK) 
GeneCards® Human Gene Database Weizmann Institute of Science (Rehovot, 
Israel) 
Illumina Experiment Manager 1.9 
 
Illumina Inc (Ense-Höingen, Germany) 
Illumina Sequencing Analysis Viewer 
1.8.37 
Illumina Inc (Ense-Höingen, Germany) 
Illumina VariantStudio Variant 
Analysis Software 2.2 
Illumina Inc (Ense-Höingen, Germany) 
Illustrator for Biological Sequences 
(IBS) 1.0.2 
The Cuckoo Workgroup (China) 
Integrative Genomics Viewer (IGV) 
2.3 
Broad Institute (Cambridge, USA) 
PyroMark Q24 Software 
 
Qiagen (Hilden, Germany) 
Quantum-Capt Image Software 
 
Montreal Biotech (Montreal, Canada) 








3.2.1 Targeted Next-Generation Sequencing (Illumina® MiSeq System) 
3.2.1.1 Design of the glioma-tailored customized gene panel 
The gene panel for the assay was previously prepared. It consisted of 518 amplicons 
covering 19 glioma-related genes: FUBP1, H3F3A, ACVR1, IDH1, PIK3CA, PIK3R1, 
TERT, HIST1H3B, BRAF, EGFR, FGFR1, PTEN, IDH2, ERBB2, NF1, TP53, PPM1D, 
CIC and ATRX, including the most commonly mutated genes in gliomas (42). 
 
3.2.1.2 Library preparation 
The major step of this technology is the preparation of a good quality library for further 
massively parallel sequencing. In this work, libraries were prepared resorting to 
Illumina® TruSeq® Custom Amplicon Low Input Library Prep Reference Guide, 
according to the manufacturer’s instructions. Each step is briefly described below. 
I. Quantification and dilution of gDNA samples 
DNA samples were quantified using a fluorometric method (QUBIT). 250ng of DNA 
were diluted in 1µl SS1, to a final volume of 5µl (water was added when needed).  
II. Hybridization of oligo pool 
Then, the hybridization of the custom oligo pool containing upstream and downstream 
oligos specific to the target regions of interest (Figure 7) was performed leading to 
replicates that increase confidence in variant calls.   
Briefly, in a 96-well PCR plate (Thermo Fisher Scientific, Germany), 2,5µl CAT, 2,5µl 
RS1 and 15µl OHS2 were added per sample well. A no template control was performed 
adding 5µl RS1, 5µl CAT and 15µl OHS2; also, an assay control was executed, adding 
2µl 2800M, 2µl RS1, 5µl ACP3 and 15µl OHS2. For 25µl reaction volume, the 





1. 95oC for 3minutes 
2. from 90oC, decrease by 0.5oC, hold for 30seconds, ramp at 0.1oC per second (60x) 
3. from 60oC, decrease by 0.5oC, hold for 1minute, ramp at 0.1oC per second (20x) 
4. from 50oC, decrease by 1oC, hold for 2minutes, ramp at 0.1oC per second (10x) 
5. from 40oC, hold for 10minutes, ramp at 0.1oC per second 
III. Removal of unbound oligos 
Unbound oligos from gDNA were removed using 25µl SPB per each well. Two wash 
steps using SW1 and a third wash step using 60% ethanol were performed to ensure 
complete removal of unbound oligos. 
IV. Extension and ligation of bound oligos 
Products containing the targeted regions of interest flanked by sequences required for 
amplification were the product of a DNA polymerase extension from the hybridized 
upstream oligo followed by ligation to the 5’ end of the hybridized downstream oligo 
using a DNA ligase (Figure 7).  
Summarily, 22 µl ELB/ELE mixture were added to each well and then the plate was run 
on a thermal cycler at 37ºC for 45min, 70ºC for 20min and hold at 4ºC. 
V. Amplification of libraries 
A unique combination of two index adapters were added to the extension-ligation 
products of each tumour DNA by PCR which were required for further cluster formation 
as well as barcoding of individual tumour sequencing reads (Figure 7).  
Succinctly, 4µl of each index i7, 4µl of each index i5 and 20µl EDP/EMM mixture were 
added to each well. Then, considering the appropriate number of PCR cycles (for 385-
700 amplicons it is 28 cycles and for FFPE samples it is added 1 more cycle, resulting in 







Initial denaturation 95 °C 3 min  
Denaturation  98 °C 20 sec  
29x Annealing  67 °C 20 sec 
Extension  72 °C 40 sec  
Final extension  72 °C 1 min  










Figure 7 - NGS library preparation overview 
The first step of the library preparation for NGS is the hybridization of a custom oligo pool containing 
upstream and downstream oligos specific to the target regions of interest (Upstream Locus-Specific Oligo 
– ULSO - and Upstream Locus-Specific Oligo - DLSO), crucial for further amplification. Then, the 
hybridized ULSO and DLSO are connected by DNA polymerase extension from the ULSO through the 
targeted region followed by ligation to the 5’ end of the DLSO using a DNA ligase, leading to the formation 
of products containing the targeted regions of interest flanked by the sequences needed for amplification. 
Index adapter oligos (A5XX and A7XX) from Illumina containing a unique sample index and P5/P7 
adapters, which are required for the template to be compatible with the flow cell for cluster formation, are 
added. At this point, extension-ligation products containing its singular barcode are ready to proceed for 







VI. Purification of libraries 
For the purifying the PCR products 36µl SPB and 25µl RSB per well were used. 
VII. Assessment of the libraries prepared 
In order to assess the success of libraries’ preparation, 1 µl of each purified library was 
run on an Agilent Bioanalyzer (Figure 8) using a DNA 1000 chip according to Agilent 
DNA 1000 Assay Protocol (Agilent Technologies, Waldbronn). The bioanalyzer traces’ 
outputs were analysed using 2100 Expert software (Agilent Technologies, Santa Clara) 
in which the PCR products for 200 bp amplicons were expected to be approximately at 
350bp size trace. 
 
 
Figure 8 - Agilent bioanalyzer to assess NGS library preparation 
Agilent bioanalyzer containing the DNA 1000 chip loaded with glioma samples and DNA ladder to assess 
the libraries’ quality 
 
VIII. Normalization of libraries 
For an effective sequencing process, it is crucial that each library has the same 
representation in pooled libraries. Briefly, 45 µl LNA1/LNB1 was added to each library 
well and washed with 45µl LNW1 for two times. 30µl of fresh 0.1N NaOH was then 
added to each well and 30 µl of its supernatant was transferred from the LNP plate to the 
corresponding well in the SGP plate which also contained 30 µl LNS2.  
IX. Pool libraries 
Equal volumes of normalized library (5µl) were combined in a single tube. Then, 12µl of 
combined libraries were diluted in 588µl hybridization buffer and heat denatured. Pooled 






Sequencing of the previously prepared libraries was performed as indicated in the MiSeq 
System User Guide and it is schematically shown in Figure 9. 
The previously prepared adapter-ligated library fragments were loaded into a flow cell 
which contained oligonucleotides complementary to Illumina adapter sequences leading 
to the hybridization of the fragments to the flow cell surface. Then, through bridge 
amplification, each bound fragment was amplified generating clonal clusters. Illumina’s 
sequencing technology employs the sequencing-by-synthesis approach in which the 
nucleotides are fluorescently labelled and act as reversible terminators of the 
amplification reaction. Then, in each cycle, the four nucleotide analogues are 
simultaneously added and incorporated by the DNA polymerase; these nucleotides are 
chemically blocked (replacement of the 3’-OH group for a 3’-o-azidomethyl group) to 
prevent the incorporation of more than one nucleotide in each cycle. Once the nucleotide 
is incorporated, the flow cell is imaged and the fluorescence emission wavelength and 
intensity recorded from each cluster are used to identify the base incorporated. The 
nucleotides that have not been used are washed away and the chemical blockade of the 3’ 
end is removed with tris-(2-carboxyethyl)-phosphine, to continue the synthesis of the 
chain. Thus, once the fluorescence signal is collected, a new cycle begins, repeating the 











Figure 9 - Representation of Illumina NGS cluster amplification and sequencing 
Single-stranded, adapter-ligated fragments are hybridized to primers immobilized on the flow cell surface; 
the free end of a hybridized fragment “bridges” to a complementary oligo on the flow cell surface; multiple 
cycles of denaturation and extension result in localised cluster amplification (bridge amplification) 
generating clusters of DNA with identical molecules. Sequencing reagents, such as DNA polymerase and 
all four fluorescently labelled nucleotides are added simultaneously to the flow cell channels for 
incorporation into the cluster fragments; the flow cell is imaged and the emission data recorded from each 






3.2.1.4 Data analysis 
Global data of the NGS run including sequence coverage and quality parameters were 
evaluated using Illumina Sequencing Analysis Viewer 1.8.37 (Illumina Inc, Germany). 
More particular sequencing outputs were analysed resorting Illumina VariantStudio 
Variant Analysis Software 2.2 (Illumina Inc, Germany) and Integrative Genomics Viewer 
(IGV) 2.3 (Broad Institute, USA). These last two bioinformatics software packages 
aligned the reads to the human reference genome GRCh37 (hg19) so the differences 
between the reference and the sequenced amplicons were easily identified (Figure 10). 
This alignment was facilitated due to the manifest file, provided by Illumina, containing 
the coordinates of the DNA fragments in the library, allowing the direct comparison of 
the sequencing reads to the respective regions of the reference genome and, in this way, 
the software does not have to look for the reads in the entire genome.  
 
 
Figure 10 - NGS data analysis methodology 
Illumina VariantStudio Variant Analysis Software 2.2 (Illumina Inc, Germany) explanatory image 
comparing NGS assay reads to reference genome in which a single-nucleotide variation T>C is observed. 
(figure adapted from (72)) 
 
➢ Filtering process 
As NGS technology provides thousands of variations for each sample, it is crucial to apply 
extra-filtering techniques to taper our research and so to minimize false positive findings. 
Illumina Sequencing Analysis Viewer (SAV) furnishes critical quality metrics generated 
by the MiSeq real-time analysis software, such as the percentage of reads identified – 
“pass-filter” (PF). This parameter, PF, is the percentage of reads which pass chastity filter, 
the internal quality filtering process of Illumina sequencers. Chastity, according to 
Illumina, is defined as “the ratio of the brightest base intensity divided by the sum of the 





call can have a chastity value below 0,6 to allow clusters pass filter (75). This first step 
of filtering clears away the least trustworthy clusters from the image analysis outputs. 
Then, using Illumina VariantStudio Variant Analysis Software 2.2, three different grades 
of filtering were applied (Table 11).  
In order to select the most reliable new-mutations and to further confirm some by Sanger 
sequencing, two major criteria were contemplated: technical issues (is the mutation true 
or false?) and biological consequence (is it damaging or benign?). To the first selection 
criteria, besides a variation frequency >20% (the higher the better), only read depths 
above 100 were considered. To the second selection criteria, only frameshift variants and 
deleterious/damaging missense variants were selected. In addition, visualization of the 
mutation on the IGV 2.3 (Integrated Genome Viewer) was performed to assess if the 
mutation seemed to be true or not: the software allows not only to see individual 
sequencing traces (forward and reverse), so one would notice if a mutation artefact only 
occurs in one sequencing direction, but also to see other sequence artefacts up- or 
downstream of a particular variant, which are both indicators of fixation artefacts. 
 
Table 11 - Filtering process performed during NGS data analysis 
The filtering process, which originated three different filtering grades, was carried concerning 4 major 
filtering settings: (i) MiSeq instrument pass filters, which consists in an internal quality filtering process of 
the sequencer; (ii) population frequency of the detected variants, which was always set to be under 5% not 
to create e.g. population polymorphisms bias; (iii) DNA variation frequency, which firstly was set to be 
higher than 10% and then higher than 20% to further restrict the outputs and (iv) biological consequences, 
which at first were all shown (intronic and exonic mutations) and then were confined only to mutations 
inside genes and further excluded splicing mutations. As such, the most stringent filter used, “very very 
stringent”, included missense, frameshift and stop gained/lost variations and inframe insertions and 
deletions with a variation frequency higher than 20%. 
Filtering process Stringent Very stringent Very very stringent 
MiSeq instrument Pass filters (e.g. strand bias) 
Population frequency < 5% 
Variation frequency >10 % > 20% 
Biological 
consequences 
All Only inside genes 
Only inside genes; 






3.2.2 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction was performed for the amplification of DNA segments of 
interest.  
Oligonucleotide primers (with approximately 20 nucleotides) are designed 
complementary to the DNA region of interest. PCR thermocycling causes denaturation 
of double-stranded DNA into single-stranded DNA allowing the primer to anneal the 
region of interest and the Taq DNA polymerase to mediate the elongation.  
This methodology leads to exponential in vitro reproduction of a nucleic acid fragment 
and it is therefore the choice for a quick amplification of a DNA segment of interest which 
is crucial for its analysis. 
In this work, PCR was performed to amplify IDH1, BRAF and H3F3A hot spot mutation 
sites (codon 132, codon 600 and codons 27 and 34, respectively) and several other 
mutation sites according to the NGS results. PCR products were further used for 
pyrosequencing or Sanger sequencing validation, correspondingly.  
 
3.2.2.1 PCR reaction setup 
The standard PCR reaction mixture consisted as described below: 
Reagent Amount 
 gDNA (25 ng/µl) 3,0 µl 
Master mix 2x 12,5 µl 
CoralLoad concentrate 10x 2,5 µl 
Forward primer 10pmol/µl 1,5 µl 
Reverse primer 10pmol/µl 1,5 µl 
Water 4,0 µl 
Total volume: 25 µl  
 
A positive-control (mutated DNA), a negative-control (WT DNA) and a blank (H2O) 





 3.2.2.2 PCR program 








In specific cases in which the PCR product was too low or non-existent, an optimization 
of the procedure was achieved by adjusting the annealing temperature to 54⁰C as well as 
the elongation time to 40sec. 
 
3.2.2.3 PCR quality control: agarose-gel electrophoresis 
Agarose-gel electrophoresis was performed to survey PCR amplification – verification of 
the quality and size of PCR products.  
Therefore, 3µl PCR-products were first used for control on a 3% agarose-gel with pUC19 
as length standard (34-501 bp). Typical 3% agarose-gels were prepared by dissolving 3g 
peqGOLD agarose in 100ml 1xTBE buffer (from 10xTBE composed by 540g tris base, 
275g boric acid, 200ml 0,5M EDTA pH 8 and water until 5l solution) and adding 8µl 
Midori Green. The gels were run for 10min at a voltage of 150V in BioRad Sub-Cell® GT 
Cell chamber. 
DNA fragments with intercalated Midori Green were visualized by UV illumination at 
254nm. The image of the agarose-gel was captured using Quantum ST4 system and 
analysed using Quantum-Capt software image enhancement.   
1. Initial denaturation 95 ⁰C 15 min  
2. Denaturation  94 ⁰C 30 sec  
50x 3. Annealing  60 ⁰C 30 sec 
4. Extension  72 ⁰C 30 sec  
5. Final extension  72 ⁰C 10 min  





3.2.3 Pyrosequencing  
This method was used to validate NGS results of almost all giant-cell glioblastoma 
samples (n = 22) for hotspot mutation in codon 132 of IDH1, in codon 600 of BRAF and 
in codons 27 and 34 of H3F3A. Two samples were not analysed by pyrosequencing 
because of lack of DNA material. 
Pyrosequencing is a technology which is based on sequence detection providing a rapid 
and accurate quantification of sequence variation (76). Sequencing by this methodology 
is achieved by a synthetic process in which nucleotides are dispensed one at a time and 
the reading is carried out as each of the four nucleotides are incorporated into the template 
strand replication (Figure 11) (65,77). 
Firstly, the DNA segment of interest is amplified by PCR using biotinylated primers so 
that the strand to serve as the pyrosequencing template is biotinylated too. The single-
stranded biotinylated template anneals with the pyrosequencing prime and this complex 
is incubated with the enzyme-mix composed by DNA polymerase, ATP sulfurylase, 
luciferase and apyrase, as well as the substrate-mix composed by adenosine 5’ 
phosphosulfate (APS) and luciferin. When the first dNTP is added to the reaction, if it is 
complementary to the base in the template strand, DNA polymerase catalyzes its addition 
to the sequencing primer. releasing a pyrophosphate (PPi) in a quantity equimolar to the 
amount of incorporated nucleotide. In the presence of APS, PPi is converted to ATP by 
ATP sulfurylase Then, using ATP as cofactor, luciferase mediates the conversion of 
luciferin to oxyluciferin generating visible light in proportional amounts to the amount of 
ATP. This light is detected by a charge coupled device camera and seen as a peak 
(pyrogram) whose height is proportional to the amount of nucleotides incorporated. In 
parallel, the unincorporated nucleotides and ATP are continuously degraded by apyrase 
to avoid these residues interfering in later cycles and enabling further dNTP additions. 
Ultimately, the complementary DNA strand is completed and the nucleotide sequence is 
determined from the set of signal peaks in the pyrogram trace (76,65,77). 
Many different assays can be executed simultaneously and the duration of each assay is 
exclusively dependent on the number of dispensations needed to cover the region of 






Figure 11 - Pyrosequencing chemistry 
DNA polymerase catalyzes the addition of a dNTP complementary to the template strand releasing a PPi 
in each incorporation. In the presence of APS, PPi is converted to ATP by ATP sulfurylase. Luciferase uses 
ATP as cofactor for the conversion of luciferin to oxyluciferin releasing light in the process. This light is 
detected by a charge-coupled device camera and seen a peak (pyrogram) whose height is proportional to 
the amount of dNTP incorporated. (figure origin: (78)) 
 
3.2.3.1 Pyrosequencing reaction setup and program 
Pyrosequencing of the PCR products was performed using pyrosequencing primers and 
the PyroMarkGold Reagents. 10µl of each PCR product was pipetted on a 8-strip 
pyrosequencing tubes in addition to 30µl mastermix composed of 18,5 µl binding buffer, 
1,5µl streptavidin-sepharose beads and 10µl HPLC-H2O. The samples were shaken for 





primers mixed with 24µl of annealing buffer was pipetted into a fresh pyrosequencing 
primer plate. The purification of the DNA-bead samples for sequencing was preformed 
resorting a vacuum prep tool as described below: 
Vacuum ON 
1 HPLC-H2O 5 sec 
2 HPLC-H2O 5 sec 
3 Samples (beads uniformly sucked) 10 sec 
4 70% EtOH 5 sec 
5 Denaturation solution 5 sec 
6 Wash-buffer 10 sec 
Vacuum OFF 
7 Primer plate (beads released  annealing) 3 min 
8 Incubate 80⁰C (denaturation)  2 min 
Vacuum ON 
9 HPLC-H2O 5 sec 
10 HPLC-H2O 5 sec 
Afterwards, the pyrosequencing plate was cooled down and placed in the PyroMark Q24 
instrument (Qiagen, Hilden). Furthermore, the pyrosequencing cartridge containing 
PyroMark enzyme-mix, substrate-mix and dNTPs was prepared according to the sample 
sheet previously elaborated using the PyroMark Q24 Software (Qiagen, Hilden) and 
placed in the sequencing instrument. At last, the USB flash drive containing the sample 
sheet (with the assays to perform and correspondent dispensation orders) is opened on the 
sequencing instrument enabling the sequence process to begin. 
 
3.2.3.2 Data analysis 
Pyrogram outputs were analysed using the PyroMark Q24 Software (Qiagen, Hilden). All 





3.2.4 Sanger sequencing  
Sanger sequencing was performed to validate 103 non-hotspot mutations selected from 
the NGS outputs. In order to assess these 103 selected mutations, primers were designed 
resorting UCSC Genome Browser (University of California, USA). 
Sanger sequencing, also known as the chain-termination method, is the gold-standard 
DNA sequencing technology and it is the process of selective incorporation of chain-
terminating dideoxynucleotides (ddNTPs) by DNA polymerase during in vitro DNA 
replication (79,80,81). 
A single-stranded DNA template, a DNA polymerase, a DNA primer, normal nucleotides 
(dNTPs) and modified nucleotides (ddNTPs) which stop DNA strand elongation are 
required to perform this method (81). 
During the sequencing, DNA polymerase incorporates nucleotides to a growing chain 
which are selected by base-pair matching to the single-stranded DNA template. DNA 
polymerase adds not only dNTPs but also its analogues, ddNTPs. As the growth occurs 
by the formation of a phosphodiester bridge between the 3’-OH group on the primer and 
the 5’-phosphate group of the incoming nucleotide, the extension of the DNA terminates 
when the ddNTPs are added due to these modified nucleotides lacking the 3’-OH group 
that is required for the ligation between two nucleotides. Therefore, chain elongation is 
terminated selectively at A, C, G or T and as each of the four ddNTPs are fluorescently-
labelled, the sequencing is read while each of the different fluorescent signs are detected 
during capillary electrophoresis, resulting in the final sequence scheme – chromatogram 
(Figure 12) (79,80,82). 
 
3.2.4.1 Sanger sequencing reaction setup  
This method was not performed in the lab. PCR products and respective designed primers 
were sent to Eurofins company to execute the assay. Thus, on each well of a prepaid 
barcoded 96-well plate (Eurofins Genomics, Germany), 10µl of PCR product and 5µl of 
water were added. Each PCR product was analysed twice – forward and reverse 
sequencing. Precisely identified, 15µL of each diluted designed primer (10pmol/µL) were 
added in 2ml tubes with safe-lock. Then, the prepared material was sent to the company 





3.2.4.2 Data analysis 
Sequencing results were sent by the company and analysed resorting BLAT search from 
UCSC Genome Browser (University of California, USA) and further compared with the 
respective previous results from NGS. 
 
 
Figure 12 - Sanger sequencing technology 
Gold-standard DNA sequencing method based on the detection of fluorescently-labelled chain-terminating 
nucleotides (ddNTPs) that are incorporated by a DNA polymerase during the replication of a template. 






4.1 Assessment of NGS libraries preparation  
At the end of each Bioanalyzer run, it was created a virtual agarose-gel by its software 
(Figure 13) allowing to assess the NGS library preparation’s success for each sample. 
With this, the analysis of DNA libraries’ quality was facilitated: the best libraries were 
scored of 3 points (strong band), good libraries of 2 (satisfactory band), poor libraries of 
1 (weak band) and the not visible libraries (no band) of 0. 90% of the libraries showed a 
successful preparation process (only 3 libraries didn’t show any band). 
 
1) Real-time bioanalyzer trace  
 
Figure 13 - Agilent bioanalyzer results for NGS libraries’ quality 
1) Real-time bioanalyzer trace representing a very good library with the expected PCR product size ~310bp 
and 2) Virtual agarose-gels performed by Agilent bioanalyzer software where it is possible to assess the 
NGS library preparation’s success: at the first two wells are represented the control samples 2800 (positive 
control) and RS1 (negative control); further, samples 1-4, 6 and 26-28 were scored of 3 (strong band); 
samples 11, 12, 14-16, 19-25 and 30 were scored of 2 (satisfactory band); samples 7, 8, 10, 17, 18 and 29 





Figure 13 - continued 
2) Virtual agarose-gels performed by Agilent bioanalyzer software  








4.2 Next-Generation Sequencing: overall analysis 
The targeted gene panel was appraised in twenty-four giant-cell glioblastoma DNA 
samples (12 from adult patients and 12 from infant patients) and in six other glioma DNA 
samples with previously known molecular diagnostics; all the DNA samples came from 
tumour tissues surgically removed and preserved through FFPE procedure.  
DNA library preparation and sequencing were prosperous in 30 of the 30 samples (100%), 
despite quality differences. 
Illumina Sequencing Analysis Viewer 1.8.37 (Illumina Inc., Germany) showed a total 
number of reads of 19.878.072 of which approximately 95,1% were successfully mapped 
- reads identified (PF) - with a 115 bp mean read length. As quality indicator it was 
obtained a median Phred quality score of 28 (Q=27,75).  
A huge diversity of genetic alterations was pinpointed including single-nucleotide 
variations, which were the most representative (~86%; C>T more frequent), followed by 
deletions (~8%) and insertions (~6%). Exonic variations were found more commonly 
(~66%) than non-exonic variations (~34%).  
ATRX, TP53, CIC and NF1 were the most commonly mutated genes among all samples. 
One of the least mutated gene, and with less variations found, was TERT (including its 
promotor), which hot spot mutations 228C>T and 250C>T were detected only in four 
samples (three of the first type and one of the second). The genes with more variants 
outputs were NF1, ATRX and EGFR.   





4.3 Impact of the filtering process on NGS data analysis 
NGS data analysis showed an average of 979 variants for each sample when no filter had 
been applied and an average of 28 variants when the most stringent filter had been 
applied. A similar rate (35 no filter : 1 most stringent filter) was observed when evaluating 
the filtering process for each gene. 
In this manner, only roughly 3% of NGS variants outputs were available to further data 
analysis procedures. 
The impact of the filtering process for each DNA sample on NGS data analysis is 
represented below (Figure 14). 
 
 
Figure 14 - Impact of the filtering process for each sample during NGS data analysis 
The more stringent the filtering process got, the less number of variants remained intact to further analysis 
use. The filtering process was capable of reducing in approximately 97% the number of variants found in 



































4.4 Correlation between quality of the DNA libraries and NGS 
outputs 
To determine if there was any correlation between quality of the DNA libraries and the 
NGS outputs, the first parameter was compared with the most significant NGS 
technological parameters: (i) the percentage of reads identified by Illumina Sequencing 
Analysis Viewer and (ii) the number of variants detected. 
 
4.4.1 DNA libraries’ quality and percentage of reads identified (PF) 
As it can be observed in Figure 15, DNA libraries with the best quality result in the 
Bioanalyzer evaluation were found to have a higher percentage of reads identified in SAV 
as well as DNA libraries with the worst quality result had lower percentage of reads 
identified. These two parameters showed to carry a statistically significant (p = 1,34E-
07) very strong positive correlation (r = 0,8).  
 
Figure 15 - DNA library’s quality of each sample and correspondent percentage of reads identified 
Dispersion plot showing a relationship between DNA libraries’ quality obtained from Agilent Bioanalyzer 
results (scored of 0 to 3, from the poorest to the greatest library quality) and the percentage of reads 
identified for each sample in Illumina Sequencing Analysis Viewer (varying from 0 to 8%).  
 
4.4.2 DNA libraries’ quality and number of variants detected 
The total number of variants detected in NGS (no filter) didn’t show any significant 
dependence with the sample DNA’s quality (r = 0,2; p = 0,2). However, when the most 
stringent filter was applied, a moderate negative correlation was observed: samples with 
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4.5 Sensitivity and specificity of NGS technology  
4.5.1 Detection of previously identified mutations  
NGS accurately detected 6 of 6 (100%) previously known hotspot mutations which had 
been identified by pyrosequencing. All of them were well-known damaging SNVs, each 
one from a different glioma sample.  
Also, functioning as negative control, NGS didn’t spot 7 of 7 (100%) specific hotspot 
mutations that had been previously assessed as wild-type by pyrosequencing analysis: 
two in IDH1 codon 132, two in IDH2 codon 172, one in H3F3A codon 27, one in H3F3A 
codon 34 and one in BRAF codon 600. 
 
4.5.2 Validation of NGS hotspot mutations results for codon 132 of IDH1, codon 
600 of BRAF and codons 27 and 34 of H3F3A with pyrosequencing 
2 of 2 samples (100%) IDH1 positive to hotspot mutation in codon 132 in NGS analysis 
were validated by pyrosequencing. NGS results showed also BRAF V600E hotspot 
mutation in five DNA samples which all five (100%) were afterwards corroborated by 
pyrosequencing analysis. Additionally, four mutations in the H3F3A gene (three K27M 
and one G34R) were detected by NGS and could be confirmed by pyrosequencing 
(100%).  
The same success rate was achieved validating the wild-type NGS results for the first two 
genes: 20 of 20 samples (100%) negatives to IDH1 hotspot mutation in codon 132 and 17 
of 17 samples (100%) negatives for BRAF hotspot mutation in codon 600 present in NGS 
outputs were all confirmed by pyrosequencing analysis.  
 





Table 12 - Detection of previously identified mutations and validation of NGS hotspot mutations 
This representative table exhibits two technologies’ results which were compared with each other -  DNA 
hotspot mutations detected first by pyrosequencing and then compared to the NGS outputs obtained (green) 
and GcGBM DNA hotspot mutations detected first by NGS and afterwards validated by pyrosequencing 
(blue). The correlation between the frequencies of the DNA variation detected by both technologies was 








































































































(A) IDH1 Wild-type 
 
(B) IDH1 Mutant R132H 
 
(C) BRAF Wild-type 
 
(D) BRAF Mutant V600E 
 
Figure 16 - Pyrogram representations of each NGS result validated for hotspot mutations in codon 
132 of IDH1, in codon 600 of BRAF and in codons 27 and 34 of H3F3A 
(A) IDH1 wild-type; (B) typical IDH1 mutant pyrogram where G>G/A, resulting in the substitution of 
arginine to histidine (R132H, 49%); (C) BRAF wild-type; (D) typical BRAF mutant pyrogram where 
T>T/A, resulting in the substitution of valine to glutamic acid (V600E, 59%); (E) H3F3A wild-type; 
typical H3F3A mutant pyrograms where (F) A>A/T, resulting in the substitution of lysine to methionine 






Figure 16 - continued 
 
(E) H3F3A Wild-type 
 
(F) H3F3A Mutant K27M  
 








Figure 17 - Comparison of an established hot spot mutation (IDH1 R132C) identified by NGS and 
pyrosequencing 
This figure shows the IGV image of a region of the IDH1 gene containing the R132C well-known mutation 
(upper part of the figure) together with its data from Illumina software containing technical settings (variant 
frequency, read depth) as well as the pyrogram of this hot spot mutation. Both technologies safely identify 
the same mutation of IDH1 with comparable variant frequencies (38,43% NGS; 40% pyrosequencing). 
 
4.5.3 Validation of NGS novel mutations results with Sanger sequencing 
At first, only 2 of 22 (~9%) new mutations selected from NGS outputs were confirmed 
by Sanger sequencing. Among the genes investigated, and the number of variations 
analysed for each one, were: BRAF (one), CIC (five), EGFR (one), FUBP1 (five), 
HIST1H3B (three), H3F3A (one), IDH1 (three), PIK3R1 (two) and PPM1D (one). These 
first confirmed mutations were one PIK3R1 deletion CTCAGTT>CTCAGTT/C (inframe 
deletion at Chr5:67589598) with 97% variation frequency in NGS and one CIC insertion 
G>G/GC (frameshift variant at Chr19:42795885) with 96% variation frequency in NGS. 
For the second set of Sanger’s validations, 81 more novel mutations identified by NGS 
were selected. 2 samples did not show a PCR product for Sanger sequencing and as such 
they couldn’t be further analysed. 32 of 79 (40,5%) new mutations analysed were 
confirmed by Sanger sequencing. Among the genes investigated, and the number of 
variations analysed for each one, were: ACVR1 (five), ATRX (nineteen), CIC (four), 





(three), PPM1D (one), PTEN (four) and TP53 (twenty-two). In this second set of 
confirmations, a richer pattern of confirmed mutations was found: 25 SNVs, 6 deletions 
and 1 insertion, with variant frequencies varying from 24,3% to 100%. A SNV found by 
NGS and further validated by Sanger sequencing is shown in Figure 18. 
Hence, a total of 103 new variants detected by NGS were selected and 101 (98%) could 
be further analysed by Sanger sequencing which in turn validated 34 of 101 (~34%) new 
mutations. 
Almost all false positive results (58,2%) were alterations C>C/T with a variation 
frequency in NGS between 21% and 93% and alterations G>G/A with a variation 
frequency in NGS between 22% and 66%.   
Some of the analysed genes had several new mutations next to each other in a sample, so 
that with just one pair of primers it was possible to assess more than one mutation. But 
all of these cases came out to be negative for all mutations. 
 
 
Figure 18 - Novel mutation identified by NGS and its Sanger sequencing further validation 
This figure shows a verified NGS result (upper part of the figure) together with the respective region 
analysed by Sanger sequencing (lower part of the figure). Both technologies identified a ATRX c.4772G>A; 
pR1515* mutation with similar frequency. This stop gain variation leads to a premature termination of the 





4.6 Extensive analysis of NGS outputs concerning the DNA variants 
landscape 
4.6.1 Most and least commonly mutated genes  
As it is shown in Figure 19, the most commonly mutated genes, transversely to all 
samples, were ATRX, TP53, CIC and NF1; the least frequently mutated genes were IDH2, 
FGFR1, TERT (including its promotor) and HIST1H3B. 
 
Figure 19 - Expeditious view of mutated genes per sample 
Global data analysis summary of genetic outputs for each sample. In red the genes mutated for sure; in 
orange the genes which are probably mutated but it’s possibly not damaging; in grey the results technically 
uncertain (lower read depths); in blank the wild-type (not mutated). “K” stands for child sample. 
 
4.6.1.1 GcGBM distinctive mutational profiles in adults and children   
A comparison between GcGBM outputs and the other control gliomas outputs was not 
performed. The only reason for inclusion of the six glioma samples was the fact that 
information on hot spot mutations were available from those cases allowing them to 
function as controls, oppositely to GcGBM whose DNA abnormalities were collected for 
the first time. Also, the difference in the samples’ proportion of each (24 of GcGBM vs 
6 control gliomas) would lead to biased results and conclusions. 
As such, looking only at GcGBM outputs, different mutated gene patterns were easily 






FUBP1 mutations were mostly detected in adult’s samples (83%) as well as PPM1D 
mutations (83%), PIK3R1 mutations (75%), and CIC mutations (67%). 
Oppositely, BRAF mutations had a higher incidence in children samples (80%) such as 
PTEN mutations (71%).  
All the other genes had a similar rate of mutants analysing adult and children samples. 
 
4.6.2 Disparities in the number of variants detected concerning different genes 
The genes with more variants outputs were NF1, ATRX and EGFR; the smallest number 
of variants was detected in the TERT gene (including its promotor), HIST1H3B and IDH2 
(Figure 21).  
A moderate correlation was observed between the number of variants detected and the 
gene size (p = 0,002) (Figure 20). 
 
 
Figure 20 - Relation between the gene size and the number of variants detected 
A moderate correlation (r = 0,7) was found concerning the gene size and the correspondent number of 
variants detected. Each circle represents a gene and, as it is shown in this graph, when the gene size was 











































I. Number of variants detected vs gene analysed – representation of the difference in the number of 
variants detected for each gene  
 
II. Number of variants (%) vs gene analysed – representation of the proportion of variants detected 
for each gene after different filtering grades were applied 
 
Figure 21 - Number of variants detected per each gene 
I. in this graph it is easily observable the colossal difference between each gene’s variants detected. NF1, 
ATRX and EGFR were the genes with more variants detected when no filter was applied; however, CIC’s 
number of variations detected overcomes EGFR’s when the most stringent filter was applied. On the 
contrary, smaller numbers of variants were detected in TERT gene (including its promotor), HIST1H3B and 
IDH2, both when no filter and when most stringent filter were applied. II. this graph displays the different 
proportion of variants detected for each gene when consecutive filtering grades were applied. BRAF was 
the gene with higher percentage of variants filtered (20,8%) and FGFR1, oppositely, was the gene with the 
shorter proportion of variants filtered (0,6%), comparing to PF outputs. Nonetheless, the filtered variants 
consisted, in general, in 1-9% of PF outputs (average 3%).  
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4.6.3 Multiple mutation sites in the same gene 
Even after applying the most stringent filter, there were cases in which a sample had the 
same gene with multiple important mutations detected (stop gains, damaging SNVs, 
deletions and insertions). These cases were mostly, but not only, found concerning the 
genes with more altogether variants found (NF1, ATRX, EGFR and CIC), that is, in the 
genes with higher size. However, all these cases which were analysed by Sanger 
sequencing came out to be negative for all mutations. An illustrative example of these 










Figure 22 - Illustration of multiple mutations detected in ACVR1 gene and in NF1 gene 
These IGV images show two examples of simultaneous detection of several mutations close to each other 
in a region of the ACVR1 gene a) and in a region of the NF1 gene b). These variants turned out to be false 
positives which point that these findings can act as an indicator of false positive data (e.g. fixation artefacts 






The classification of gliomas into subtypes based not only on histological features but 
also molecular markers has come a long way (16). Last year, the 2007 WHO classification 
of brain tumours was revised and changed considerably due to the increased demand of 
molecular analysis for establishing a more accurate diagnostics of gliomas which has 
originated the 2016 WHO new classification already including genetic markers in the 
glioma diagnostic pathway, in addition to the histological features traditionally 
considered  (42,14). Currently, diagnostic neuropathology laboratories apply individual 
testing for selected biomarkers, such as mutations in IDH1/2, TERT, BRAF, ATRX and 
H3F3A as well as 1p/19q codeletion (42). These individual assessments are performed 
resorting to immunohistochemistry with mutation-specific antibodies against IDH1-
R132H, BRAF-V600E and H3-K27M, fluorescence in situ hybridisation (FISH) for 
detection of 1p/19q codeletion and tumour DNA sequencing through classical Sanger 
sequencing or pyrosequencing for detection of individually selected mutations 
(42,84,85,86,87). However, novel genetic abnormalities are continuously arising (42) and 
as more research into the different genetic features among gliomas is performed, further 
insight into the diagnostic, prognostic and therapeutic value will be acquired (47). 
Hereby, the application and validation of a new diagnostic method capable of performing 
robust molecular profiling in brain tumours is increasingly required in order to improve 
their management (42,64,63). Recent studies pointed out that NGS-based approaches 
making use of commercial or customized gene panels fulfil this need and so may become 
a valuable tool in future glioma diagnostics providing a cost and time efficient alternative 
to currently used conventional sequencing techniques (42,41,67). 
In this work a NGS customized gene panel for diagnostic sequencing of 19 genes 
frequently aberrant in gliomas was successfully established and verified.  
The process of DNA preparation and sequencing was found to operate greatly, holding a 
very good quality score. With roughly one week of preparation of 30 libraries and three 
days of sequencing them and obtaining the outputs, hundreds of genetic variants for each 
sample were collected. This contrasts with conventional technologies, such as 
pyrosequencing and Sanger sequencing in which each sequencing reaction evaluates only 





The filtering proceedings were impetuous concerning the data analysis, reducing in 
approximately 97% the number of variants found in the NGS run, remaining 3% reliable 
to further data analysis procedures. However, this 3% still represent a great amount of 
data, which not all are real or clinically important. In this way, and as mentioned in 
previous studies (64,67,73),  it is crucial to point the huge impact of the filtering process 
when NGS technology is used and so the need of further studies to continue the discovery 
of the best track to do it so the remain variants are worth taking in account for being 
clinically relevant to the diagnostics of brain tumours. 
In this work, it was observed the importance of the library preparation concerning the 
NGS outputs. Only 10% of the libraries didn’t have a successful quality result in the 
Bioanalyzer assessment, even though they showed sequencing results on NGS. As it was 
displayed before, DNA libraries with the worst quality result had lower percentage of 
reads identified in the NGS technology. So, the same way that in other sequencing 
technologies better quality libraries ease and accurate the sequencing process (88), the 
NGS results lead us to a similar conclusion that as the DNA quality rises, the easier is to 
this technology to sequence the DNA. Also, considering the number of DNA sequence 
changes detected in NGS, no significant correlation was found between this parameter 
and the DNA quality when no filter had been applied but when the most stringent filter 
was applied, samples with better DNA quality had generally less variants detected. These 
findings point, once again, that the filtering process is imperative to the NGS data analysis 
carrying a different impact on the results of a good or a bad library, restricting more 
effectively the outputs of the better than of the worse. With this, better DNA quality 
libraries present more reliable results showing less DNA sequence changes.  
TruSeq NGS method demonstrated to hold an immense sensitivity and specificity for 
detection of diagnostically relevant DNA variants such as hotspot mutations in IDH1 
(R132), H3F3A (K27;G34), HIST1H3B (K27), BRAF (V600) and TERT promotor 
(C228), showing a high concordance with the single-gene approach results previously or 
further performed. In the same sample presenting an IDH1 mutation previously identified 
by pyrosequencing, the 1p19q codeletion biomarker had been also previously detected 
and, curiously, for this sample, NGS showed an insertion in CIC gene (96% variation 
frequency) later confirmed by Sanger sequencing. This fact is consistent with formerly 
reported data in which authors conclude that there is a high correlation between CIC 





glioma panel does not allow a quantitative assessment of chromosomal arms 1p and 19q, 
the presence of CIC mutation and FUBP1 mutation together with an IDH1 mutation 
clearly confirms the diagnostics of an oligodendroglioma for this tumour specimen (14).  
NGS also identified several novel mutations in the 19 genes collection. In the first set of 
new-mutations analysed by Sanger sequencing, only 9% could be confirmed. 95% of the 
false-positives were SNVs C:G > T:A, which were probably formalin-induced artefacts 
(cytosine deamination to uracil, frequently found in ancient DNA) – Figure 23 -, showing 
the difficulty of NGS to identify FFPE tissue artefacts which is in line with previous 
studies (91,92). In this manner, no reliable conclusion could be pointed because these 
mutations represented 86% of the novel mutations selected to assess. As such, a larger 
second set of confirmations was performed in order to eliminate the bias that resulted 
from selecting bad DNA/NGS data on the first selection of variants. In this second set, 
the results improved substantially and one could validate 41% of the selected new 
mutations. Thus, a total of 101 selected new-mutations detected by NGS were further 
analysed by Sanger sequencing which has validated 34 of them (34%). Nevertheless, most 
of the selected mutations from NGS outputs came out to be negative and SNVs C:G > 
T:A still represented the majority of the novel mutations selected and 58,2% of the false-
positive DNA variant calls in NGS analysis. Currently, there are not enough facts about 
the veracity of this kind of variants and in order to correctly evaluate NGS capability to 
detect real novel mutations, two approaches should be further studied: (i) performing a 
treatment of the FFPE-DNA with uracil–DNA glycosylase (91); (ii) choosing other type 
of novel mutations detected by NGS to further confirm with Sanger sequencing, such as 
deletions, insertions and SNVs avoiding C:G > T:A.  
All the results presented on the extensive analysis of NGS outputs concerning the genes’ 
variants landscape demand deeper studies. Nonetheless, in general, the most commonly 
mutated genes detected in our diversified samples and the distinctive mutational profiles 
found in adults and children GcGBMs were consistent with the overall gliomas’ 
molecular characterizations displayed in Table 1. However, and once again, further 








Figure 23 - Known effects of fixation process in DNA quality 
Formaldehyde, the principal constituent of formalin, is highly reactive with DNA bases and proteins leading 
to several types of damages which are found in DNA extracted from formalin-fixed tissues. As such, the 
DNA loss of quality can be due to histone–DNA crosslinks (1); formaldehyde–DNA adducts (2); DNA–
protein crosslinks (3); DNA–DNA crosslinks (4); deamination of cytosine and 5-mC resulting in uracil (5) 
and thymine (6), respectively; loss of DNA bases resulting in abasic sites (7); fragmentation of DNA (8) 
due to DNA strand breakage. (figure adapted from (92)) 
 
Concerning the disparities in the number of variants detected in the different genes, the 
results obtained were quite the expected: bigger genes had generally more variants 
pointed by NGS technology. Also, these same genes (and not only) showed multiple 
damaging mutation sites simultaneously. However, some of these findings were analysed 
and all came out to be false positives. As such, this information of multiple variants close 
to each other as detected by the IGV can be used as an indicator of false positive data 
(e.g. fixation artefact C>T and G>A transitions). Nonetheless, further studies are needed 
to continue the evaluation of these simultaneous mutations because if any turns out to 
really be positive, it would be a bright new challenge to deeper understand glioma’s 
physiopathogenesis, because a question stands: why should a gene have more than one 
damaging mutation? 
Concerning costs, expenses for the 19-gene panel NGS was comparable to all applied 
PCR/Sanger sequencing/pyrosequencing assays. 
The central limitation of this study, besides the short period of research time, relates to 
the fact that the present gene panel only assesses 19 glioma-related genes, not covering 
certain genetic abnormalities known to also contribute to the physiopathogenesis of some 
glioma types, such as structural alterations like 1p19q codeletion in oligodendrogliomas 





(87)) and gene fusions (e.g. KIAA1549-BRAF in pilocytic astrocytomas (93); RELA in 
ependymomas (14,94)). However, these assessments would be easily achieved by: (i) 
complementing the gene panel with additional glioma candidate genes when 
diagnostically required allowing mutational and copy number analysis (42) and (ii) in 
case of gene fusions detection, specifically designing panels based on transcriptomic 
sequencing (63). 
The same way diagnostic and prognostic biomarkers may be detected with NGS gene 
panel approach, individualized therapy strategies can be feasible through molecular 
analysis resorting to NGS gene panels covering the potential targets of the available 
drugs. Currently, the only clinically relevant predictive biomarker for malignant gliomas 
which is capable of guiding therapeutic stratification is O6-methylguanine DNA 
methyltransferase (MGMT) promoter methylation in GBM patients – MGMT + leads to 
an increased response to Temozolomide treatment (11). However, the assessment of 
MGMT methylation status requires independent analysis, which is also a limitation of this 
NGS-based approach.  
 
Hence, despite NGS promising applicability in detection of diagnostic, prognostic and 
targeted treatment biomarkers and its great results in the present study, further studies to 
standardize pipelines for filtering and for interpretation of genetic variations critical for 
clinical decision-making are still crucial to enhance NGS safe use in routine diagnostics 






WHO 2016 classification of CNS tumours have recently included molecular parameters 
in addition to histological features for establishing the diagnostics of gliomas, enhancing 
the increased importance of these in the clinical outcomes and, so, in the tumour 
management. Currently, single-gene approach technologies are the gold standard to 
perform the molecular diagnostics of gliomas. However, NGS gene panels-approach 
provides the opportunity to analyse a large set of molecular targets in a massively 
paralleled way with a low DNA material input and, as such, may become a valuable tool 
in future glioma diagnostics providing a cost and time efficient alternative to currently 
used conventional pyro- and Sanger sequencing techniques.  
Hence, the aim of this study was to apply and verify if NGS could effectively replace the 
conventional single-gene approach techniques to perform the molecular diagnostics of 
gliomas. Therefore, it was established and verified a customized NGS gene-panel for 
diagnostic sequencing of 19 genes frequently aberrant in gliomas allowing to assess NGS 
ability to detect well-known hotspot mutations and to correctly identify new-mutations 
through a comparison of its results with the gold-standard sequencing methods for 
molecular diagnostics of gliomas. 
The process of DNA preparation and sequencing worked marvellously, carrying a very 
good quality score. It took only one week of preparation of 30 libraries and three days of 
sequencing them and obtaining the outputs to collect hundreds of genetic variants for each 
sample. The filtering process had a huge impact in data analysis by reducing in a great 
amount the NGS outputs to further evaluation. Library preparation also showed to 
considerably influence the DNA sequence changes detected by NGS in which samples 
with better libraries generally presented higher percentage of reads identified and less 
variants detected. Moreover, the filtering process exhibited different impact in the results 
of different quality libraries, confining more effectively the data of the better ones. NGS-
gene panel showed 100% concordance with the pyrosequencing results previously and 
further performed concerning the detection of diagnostically relevant DNA abnormalities 
such as hotspot mutations in IDH1, H3F3A, HIST1H3B, BRAF and TERT promotor. On 
the other hand, the validation of new-mutations detected by NGS displayed a poorer 
pattern, only confirming 34% by Sanger sequencing analysis. Nonetheless, the majority 





the main source of most false positives. Further, genes with higher size showed generally 
a higher number of variants detected by NGS and they commonly presented multiple 
damaging mutation sites simultaneously which all came out to be false positives in Sanger 
sequencing analysis leading to conclude that this information can be further used as an 
indicator of false positive data (e.g. fixation artefact).  
Despite the large amount of filtered data, hundreds remained to be analysed. More time 
would be needed to continue the verification of new-mutations detected by NGS allowing 
stronger and more reliable conclusions. Anyway, further studies are crucial to continue 
to try to find the best way to filter NGS outputs in order to collect mostly the real and 
clinically relevant variants, which is still the major obstacle of NGS use in routine 
molecular diagnostics. Additionally, and trying to overcome NGS difficulty to identify 
FFPE-DNA artefacts, a treatment of the FFPE-DNA with uracil-glycosylase and a better 
pattern of mutation selection to further validation can be used in future work to more 
accurately assess the ability of NGS to detect real new-mutations. 
Due to the fact that the NGS-gene panel studied only assessed 19 glioma-related genes 
and couldn’t evaluate certain genetic abnormalities important in glioma pathophysiology, 
future research complementing the gene panel and allowing copy number analysis and 
gene fusion detection would enrich the present conclusions concerning NGS ability to 
correctly detect genetic abnormalities valuable for glioma molecular diagnostics and 
would improve even more the knowledge of the molecular pathology of gliomas. 
 
In summary, with the majority of good results obtained, one can point out that NGS-based 
approach is indeed a potential substitute for the conventional technologies to perform the 
molecular diagnostics of brain tumours. However, despite NGS immense ability to 
furnish important sequencing data in a time and cost more efficient way than conventional 
technologies, it is not possible to argue its application in glioma routine molecular 
diagnostics at the current time due to its cloudy results concerning the new-mutations 
detected. Consequently, NGS safe use in its wide range of potential clinical applications 
(diagnostics, prognostics, targeted treatment) must be delayed until it is established clear 
standard pipelines for filtering and for interpretation of genetic variations critical for 
clinical decision-making. Hence, it is crucial to pursue the path of extended research of 
this NGS technology in order to increase the quality and accuracy of its use and, then, to 
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A.3 Illumina Sequencing Analysis Viewer (SAV): software landscape 






A.4 Reads mapped to indexes from Illumina Sequencing Analysis 
Viewer 








A.5 Illustration of Illumina VariantStudio Variant Analysis Software 
This software allows us to choose the sample to further analyse and set diverse filtering 
parameters. It displays, among others, an illustrative representation of the genetic variant 
within the gene (exons, introns and site of mutation clearly designed), the gene 
abbreviation, the variant type, the genomic location, the variant frequency, the read 
depths, the consequence and if it is deleterious/damaging or tolerated/benign. Also, this 
software is connected with several databases (e.g. COSMIC) allowing a quicker 








A.6 Number of variants per sample detected by NGS technology  
NGS results showing the difference in the number of variants obtained for each sample 
when no filter A) vs the most stringent filter B) were applied. 
 
A) No filter  
 





























































































































A.7 Primers designed for validation of the selected NGS novel 
mutations with Sanger sequencing 
Several of the primers listed, which were designed for further confirmation of the new-
mutations detected by NGS, were capable of assessing more than one mutation detected.  
 
a. Primers designed for amplification of gDNA for the first set of Sanger sequencing validations of 
the selected new mutations detected by NGS 
Sample ID Gene amplified Primer sequence 
4099 HIST1H3B 
fw: 5’ TCTTGCGAGCAGCCTTGG 3’ 
rev: 5’ AGACGTCTCTGCAGGCAAGC 3’ 
4099 IDH1  
fw: 5’ TTACCCATCCACTCACAA 3’ 
rev: 5’ GAAGCATAATGTTGGCGTC 3’ 
4101 H3F3A 
fw: 5’ TCAATGCTGGTAGGTAAG 3’ 
rev: 5’ TTGTAGCCAGTTGCTTCC 3’ 
4101 FUBP1  
fw: 5’ AGTACTCTTCCCAAGCCTTG 3’ 
rev: 5’ ACCCTCACTGTCACATTGCA 3’ 
4101 FUBP1 
fw: 5’ TCCCAGTTGGCACAATAA 3’ 
rev: 5’ TAATCCTGGTGGACCTGGAC 3’ 
4101 FUBP1 
fw: 5’ TGCGAACACCAGCATCAT 3’ 
rev: 5’ AACCCTGAGAAGCTAGCTT 3’ 
4101 FUBP1 
fw: 5’ TACCATGAGAATGTAACA 3’ 
rev: 5’ CTAACTAGTAATTGGCAGAGG 3’ 
4101 HIST1H3B  
fw: 5’ TTGGTAGCCAGCTGCTTGCGT 3’ 
rev: 5’ ACGTCTCTGCAGGCAAGCTT 3’ 
4101 EGFR 
fw: 5’ TCTGTCACTGACTGCTGTGA 3’ 
rev: 5’ ATTCCCTGCCTCGGCTGACATT 3’ 
4101 BRAF 
fw: 5’ GTAACTCAGCAGCATCTCA 3’ 
rev: 5’ TTGGTCTAGCTACAGTGA 3’ 
4101 PPM1D 
fw: 5’ GATACAGATGTAGTGGCAGC 3’ 
rev: 5’ ATCTGCTCGGAGCATACGCT 3’ 
4101 CIC 
fw: 5’ ACAGCTCACCCTGGCCTAT 3’ 
rev: 5’ ACCTTCTGAGGCTGAGAGGT 3’ 
4101 CIC 
fw: 5’ AGCCAGGCTGGAACAGTCA 3’ 
rev: 5’ CCCTCACCTGAGAGCAGG 3’ 
4101 CIC 
fw: 5’ AGCTGCCGCCTGCCTGTG 3’ 






fw: 5’ GCCAACATGACTTACTTGATCC 3’ 
rev: 5’ AATATTCTGGGTGGCACGGTC 3’ 
4107 PIK3R1 
fw: 5’ TCTAGGATCAAGTTGTCA 3’ 
rev: 5’ AACTCACCTGGGATGTGC 3’ 
4107 PIK3R1 
fw: 5’ GCCAATATTCACTGGTGGAAG 3’ 
rev: 5’ AAGTGCCATCTCGCTTCCCT 3’ 
R-78610 CIC 
fw: 5’ AGCCACTGCCACTGGTGA 3’ 
rev: 5’ ACATCCAGCAGGTAGAGAG 3’ 
 
b. Primers designed for amplification of gDNA for the second set of Sanger sequencing validations 
of the selected new mutations detected by NGS 
Sample ID Gene amplified Primer sequence 
585 PTEN 
fw: 5’ TTGCAAATGTTTAACATAGG 3’ 
rev: 5’ ACTGACCTTAAAATTTGGAG 3’ 
588 TP53 
fw: 5’ AATCAGTGAGGAATCAGAGG 3’ 
rev: 5’ CAAGATGTTTTGCCAACTGG 3’ 
588 NF1 
fw: 5’ CATAAAATTACCCAAGTTGC 3’ 
rev: 5’ TGTTATAGTTGGGCAAGAGG 3’ 
588 ATRX 
fw: 5’ TCTTCCTCTTCCTTAAGAGC 3’ 
rev: 5’ ATGACTTTGTACTGTTTACC 3’ 
4118 TP53 
fw: 5’ AAGGGACAGAAGATGACAGG 3’ 
rev: 5’ GGATGATTTGATGCTGTCC 3’ 
4118 NF1 
fw: 5’ TTGTCCACATTAGGCTTAGG 3’ 
rev: 5’ AGAACAAGGAACCACATTGG 3’ 
4119 TP53 
fw: 5’ TTGCTTACCTCGCTTAGTGC 3’ 
rev: 5’ ATTTCCTTACTGCCTCTTGC 3’ 
4119 ATRX 
fw: 5’ ACCCTTTCTTCTGTTTCTGC 3’ 
rev: 5’ TCTGAAGAATCTAAGAAGCC 3’ 
4120 ERBB2 
fw: 5’ TCGCTCACAACCAAGTGAGG 3’ 
rev: 5’ GGTTTCAATGACGGTGAAGG 3’ 
4120 TP53 
fw: 5’ CTCCTGACCTGGAGTCTTCC 3’ 
rev: 5’ CTTGGGCCTGTGTTATCTCC 3’ 
4121 NF1 
fw: 5’ GTGGGTCTAGAATTGAGTCC 3’ 
rev: 5’ TCCTAAGAGGCAAGCTGACC 3’ 
4121 NF1 
fw: 5’ CTGGTTATATCTGCATTAGG 3’ 
rev: 5’ GGAGAAGCTGAAATAGAACC 3’ 
4121 NF1 
fw: 5’ TTATTTCTGGACAGTCTACG 3’ 
rev: 5’ GCAAGTCCTATGAACTTATC 3’ 
4121 NF1 
fw: 5’ TTGCTTACGACAACGTCTCC 3’ 






fw: 5’ ACTGACAACCACCCTTAACC 3’ 
rev: 5’ TCAGCATCTTATCCGAGTGG 3’ 
4121 CIC 
fw: 5’ CTGAGTCTGCTTCTGTTTGG 3’ 
rev: 5’ TCACTCTCTAACCGCCTTCC 3’ 
4121 ATRX 
fw: 5’ GGGAACCCTCAACAACAAGG 3’ 
rev: 5’ CGTTTCAACATACCAACTGG 3’ 
4121 ATRX 
fw: 5’ CAACTGAACTCTGAACTTCC 3’ 
rev: 5’ TCAGAATGTTCCAACAGAGG 3’ 
4125 NF1 
fw: 5’ CTAGCAGAAATTATATCAATGAG 3’ 
rev: 5’ AGACAAGCTATGTCTTGACC 3’ 
4125 ACVR1 
fw: 5’ ACTGTCCATTCTTCTTAACC 3’ 
rev: 5’ CATTATCATGAAATGGGATCG 3’ 
4125 ATRX 
fw: 5’ TCAGGTAACTTTTCAGTGCC 3’ 
rev: 5’ AGAGCAAGCATCTCAAAACC 3’ 
4125 H3F3A 
fw: 5’ AAATCGACCGGTGGTAAAGC 3’ 
rev: 5’ TACAAGAGAGACTTTGTCCC 3’ 
4125 PTEN 
fw: 5’ TCCTTTTGAAGACCATAACC 3’ 
rev: 5’ AAACCCAAAATCTGTTTTCC 3’ 
4125 TP53 
fw: 5’ GCAAATGCCCCAATTGCAGG 3’ 
rev: 5’ AAGCGAGGTAAGCAAGCAGG 3’ 
4129 TP53 
fw: 5’ CTGGAGGGCCACTGACAACC 3’ 
rev: 5’ GTCCCCAGGCCTCTGATTCC 3’ 
4129 EGFR 
fw: 5’ TCTTCCAGTGTTCTAATTGC 3’ 
rev: 5’ AACACAGTGACATGAGATGC 3’ 
4129 NF1 
fw: 5’ AAGTCGTCATGTCACTTAGG 3’ 
rev: 5’ AACCCACTAATACTTGAAGG 3’ 
4142 NF1 
fw: 5’ CCCTGTTGTAAGTCCTATGG 3’ 
rev: 5’ CTTCATCAATTCCAGGCAGG 3’ 
4142 EGFR 
fw: 5’ AATCCAACAAATGTGAACGG 3’ 
rev: 5’ AACTGAACCTGTGACTCACC 3’ 
4142 TP53 
fw: 5’ CCTAAGAGCAATCAGTGAGG 3’ 
rev: 5’ TGCAGCTGTGGGTTGATTCC 3’ 
4142 CIC 
fw: 5’ CAGCCTTCTCAAGGGGTCTGC 3’ 
rev: 5’ CTGCTCTCGCTGCTGCCACC 3’ 
4142 ATRX 
fw: 5’ GCATGTGCTCACTATCTACC 3’ 
rev: 5’ TTCCGAGTTTCGAGCGATGG 3’ 
4153 TP53 
fw: 5’ TGTTGTTGGGCAGTGCTAGG 3’ 






fw: 5’ TGTCCCAGAATGCAAGAAGC 3’ 
rev: 5’ TTTCACCCATCTACAGTCCC 3’ 
4153 ATRX 
fw: 5’ ACCATAGTCTACTGTACTGG 3’ 
rev: 5’ TAAATTTTCGTCAGGTCTGC 3’ 
4153 ATRX 
fw: 5’ GCATGTGCTCACTATCTACC 3 
rev: 5’ GAAGGCTCATCTTGCATTGG 3’ 
4153 ACVR1 
fw: 5’ TGGATTCCATTCTGACAACC 3’ 
rev: 5’ AAGCCAGTTTGTCATTGTGG 3’ 
4155 TP53 
fw: 5’ TGGAAGAAATCGGTAAGAGG 3’ 
rev: 5’ CTTGGGCCTGTGTTATCTCC 3’ 
4155 ATRX 
fw: 5’ CTATGGAACATATTTGTACC 3’ 
rev: 5’ TCTCTTAGATCATTGTATGG 3’ 
4158 PTEN 
fw: 5’ ACCACAGTTGCACAATATCC 3’ 
rev: 5’ AAATCTAGGGCCTCTTGTGC 3’ 
4158 TP53 
fw: 5’ AGGCATAACTGCACCCTTGG 3’ 
rev: 5’ TGGGAGTAGATGGAGCCTGG 3’ 
4158 ATRX 
fw: 5’ AGAACTGTGACTCATCCTGC 3’ 
rev: 5’ ATGTAATGAAACAGTTAAGG 3’ 
4160 NF1 
fw: 5’ TTTCTCCTAGGTCAGCTGCC 3’ 
rev: 5’ CGTGAGGTGTGGCTCATTGG 3’ 
4160 TP53 
fw: 5’ GCTTTCCAACCTAGGAAGGC 3’ 
rev: 5’ TTACTTCTCCCCCTCCTCTG 3’ 
4160 ATRX 
fw: 5’ TTTACAGCATCCATCGCTCG 3’ 
rev: 5’ CCTGTTCTGGCTCTGTAACC 3’ 
4160 PIK3R1 
fw: 5’ GGAAATGATCGATGTGCACG 3’ 
rev: 5’ GCAAGACATATACAAGCACC 3’ 
P-3879 NF1 
fw: 5’ CAAATATATGTCTTCCACCC 3’ 
rev: 5’ TGAATGTGTTATAGTTGGGC 3’ 
P-3879 CIC 
fw: 5’ CACCATGGTCACCAATGTGG 3’ 
rev: 5’ AGGTTAGTGACAGTGGCAGG 3’ 
P-3879 ATRX 
fw: 5’ ATATGTTTACCTTTGGCAGC 3’ 
rev: 5’ TTCATATTAACCAGTAACCG 3’ 
R-77342 NF1 
fw: 5’ TTTTCTCCTAGGTCAGCTGC 3’ 
rev: 5’ ATTCTAACGTGAGGTGTGGC 3’ 
R-77376 ACVR1 
fw: 5’ AAGAATCGAAACAATCCACC 3’ 
rev: 5’ AGTGTATTGCAACAGTGACC 3’ 
R-78222 TP53 
fw: 5’ GTTGCAAACCAGACCTCAGG 3’ 






fw: 5’ GGAAGAAGACTTGAAGAAGC 3’ 
rev: 5’ TTTCATTGCCCAACCACTCG 3’ 
R-78653 NF1 
fw: 5’ GCATGAGAAATCATTCTAGC 3’ 
rev: 5’ AACATTCAACACTGATACCC 3’ 
R-78653 TP53 
fw: 5’ CAGGCATTGAAGTCTCATGG 3’ 
rev: 5’ CAATGGTTCACTGAAGACCC 3’ 
R-78653 ATRX 
fw: 5’ CAAATTTCTTCTCGCTCAGG 3’ 
rev: 5’ AGAGCAAGCATCTCAAAACC 3’ 
 
 
A.8 Results of validation of the selected NGS novel mutations with 
Sanger sequencing  
Illustrative tables representing each of NGS novel mutations selected with its major 
features (variant frequency and read depths) and the Sanger sequencing results – if the 
mutation is real (confirmed) or if it’s a false positive (WT). I represents the first 22 
mutations analysed, which only 9% were confirmed and II represents the further 81 
mutations selected, which 40,5% were validated. 
 
I. Results of the first set of Sanger’s validations 
DNA Gene Mutation 
Alt var freq 
(%) 
Read depth Result 
P4101 BRAF C>C/T 20,84 403 WT 
P4101 CIC C>C/T 33,7 629 WT 
P4101 CIC C>C/T 36,24 367 WT 
P4101 CIC G>G/A 46,84 1106 WT 
P4101 CIC C>C/T 20,8 697 WT 
R78610 CIC G>G/GC 96,19 105 CONFIRMED 
P4101 EGFR TC>TC/T 22,49 498 WT 
P4101 FUBP1 G>G/A 44,19 525 WT 
P4101 FUBP1 G>G/A 43,38 521 WT 
P4101 FUBP1 C>C/T 27,18 916 WT 
P4101 FUBP1 C>C/T 28,95 950 WT 
P4101 FUBP1 G>G/A 60,54 223 WT 
P4099 HIST1H3B C>C/T 24,08 1711 WT 





P4101 HIST1H3B C>C/T 32,88 587 WT 
P4101 H3F3A C>C/T 25,9 2849 WT 
P4099 IDH1 C>C/T 28,25 1521 WT 
P4099 IDH1 G>G/A 46,57 3487 WT 




97,25 255 CONFIRMED 
P4107 PIK3R1 C>C/T 98,68 228 WT 
P4101 PPM1D C>C/T 45,51 690 WT 
 
II. Results of the second set of Sanger’s validations 
DNA Gene Mutation 





P4125 ACVR 1 G>G/A 34,9 1209 WT 
P4153 ACVR1 G>G/A 50,18 1706 CONFIRMED 
R77376 ACVR1 C>C/T 39,19 694 CONFIRMED 
P4099 ACVR1 CG>C 43,1 928 WT 
P4109 ACVR1 T>T/C 22,02 1694 WT 
P3879 ATRX C>C/T 34,52 1008 CONFIRMED 
P4119 ATRX T>T/A 43,88 4756 WT 
P4121 ATRX C>C/T 51,96 460 WT 
P4121 ATRX G>G/A 42,52 1129 WT 
P4125 ATRX G>A/A 99,85 682 WT 
P4142 ATRX T>T/A 26,12 1252 WT 
P4153 ATRX G>G/A 76,62 1065 CONFIRMED 
P4153 ATRX T>T/G 92,37 2149 CONFIRMED 
P4155 ATRX G>G/T 32,05 571 WT 
P4158 ATRX C>C/G 35,2 2835 CONFIRMED 
P4160 ATRX G>G/A 21,67 1117 WT 
P4160 ATRX G>G/A 22,6 1137 WT 
P588 ATRX TTCC>TTCC/T 92,85 3663 WT 
R78653 ATRX TAA>TAA/T 90,79 3126 CONFIRMED 
P585 ATRX TTCC>TTCC/T 3,06 686 WT 
P748 ATRX G>G/A 72,79 2870 CONFIRMED 
P4101 ATRX CT>CT/C 24,96 669 WT 
P4102 ATRX CG>CG/C 37,82 743 WT 
P4111 ATRX TG>TG/T 22,68 626 WT 
P4121 CIC C>T/T 100 165 WT 
P4142 CIC G>G/A 28,98 1042 WT 





P3879 CIC G>G/A 46,13 388 WT 
P4129 EGFR C>C/T 21,58 709 WT 
P4142 EGFR C>C/T 25,63 1662 WT 
P585 EGFR C>C/T 49,24 3109 CONFIRMED 
P4120 ERBB2 G>A/A 100 139 WT 
P4125 H3F3A G>G/A 66,22 1350 WT 
P4118 NF1 T>C/C 100 584 WT 
P4121 NF1 G>G/A 59,92 781 WT 
P4121 NF1 C>C/T 40,68 799 CONFIRMED 
P4121 NF1 ACT>ACT/A 52,94 850 WT 
P4121 NF1 AG>AG/A 34,51 988 WT 
P4125 NF1 G>A/A 99,12 455 
NO PCR 
PRODUCT 
P4129 NF1 G>G/T 21,19 670 WT 
P4142 NF1 C>C/T 32,2 531 WT 
P4160 NF1 G>G/T 35,36 577 WT 
P588 NF1 AC>AC/A 55,16 7408 CONFIRMED 
R78653 NF1 CACTT>CACTT/C 77,35 1289 CONFIRMED 
P4107 NF1 C>T/T 100,00 512 WT 
P4109 NF1 G>G/T 34,78 1225 WT 
P3879 NF1 A>A/AC 24,3 7753 CONFIRMED 
R77342 NF1 G>G/T 31,21 676 WT 
P4099 PIK3CA C>C/T 29,35 1550 WT 
P4102 PIK3CA A>A/T 30,61 735 WT 
P4160 PIK3R1 GA>GA/G 25,38 1249 WT 
R78610 PIK3R1 AGAC>AGAC/A 46,76 1929 CONFIRMED 
P4099 PIK3R1 G>G/A 30,37 1936 WT 
P4102 PPM1D AG>AG/A 26,04 1102 WT 
P4125 PTEN C>C/T 45,12 1507 
NO PCR 
PRODUCT 
P4158 PTEN G>G/A 33,18 434 WT 
P585 PTEN C>C/T 82,27 908 CONFIRMED 
P748 PTEN C>C/T 62,36 2309 CONFIRMED 
P4110 PTEN CCAGT>CCAGT/C 40,75 1460 CONFIRMED 
P4118 TP53 AG>AG/A 96,84 412 WT 
P4119 TP53 C>C/T 92,85 1049 WT 
P4120 TP53 C>C/T 27,84 862 WT 
P4121 TP53 C>T/T 100 1737 CONFIRMED 
P4125 TP53 T>T/A 97,76 491 WT 





P4142 TP53 G>G/C 27,97 6195 CONFIRMED 
P4153 TP53 G>G/A 48,56 1979 CONFIRMED 
P4153 TP53 G>G/A 47,57 3786 CONFIRMED 
P4155 TP53 C>C/T 39,83 4115 CONFIRMED 
P4158 TP53 G>G/A 50,68 1178 CONFIRMED 
P4160 TP53 G>G/A 98,69 153 CONFIRMED 
P588 TP53 C>C/T 57,11 11955 CONFIRMED 
R78222 TP53 G>G/A 42,4 1988 CONFIRMED 
R78653 TP53 A>A/C 54,98 2008 CONFIRMED 
P585 TP53 C>C/T 74,04 11599 CONFIRMED 
P748 TP53 C>C/T 66,51 7095 CONFIRMED 
P4102 TP53 T>T/C 32,00 1847 WT 
P4107 TP53 C>T/T 99,42 859 WT 
P4109 TP53 A>A/C 76,2 6526 CONFIRMED 
P4110 TP53 A>A/AG 30,71 1234 CONFIRMED 
P4099 TPP53 G>G/A 32,21 2136 WT 
 
